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SUMMARY 
Protein glycosylation is an essential protein modification existing in all domains of life. 
About 2% of the human genome is involved in the glycosylation machinery and 50% of 
the human proteins are modified with glycans. In the endoplasmic reticulum, N-linked 
protein glycosylation begins with the assembly of an oligosaccharide precursor by step-
wise transfer of sugar building blocks to a membrane-embedded, reduced polyprenol 
anchor called dolichol-phosphate. The fully assembled N-linked glycan precursor is then 
transferred co- or post-translationally to defined asparagine residues of target proteins. 
Considering the abundance of N-glycosylated proteins throughout all human cell types, 
inherited glycosylation defects called congenital disorders of glycosylation (CDG) show 
multi-systemic involvement due to developmental defects in children. Most CDG involve 
a neurological component resulting in psychomotor retardation. Among the most 
common symptoms are epilepsy, hypotonia, hyporeflexia, strabismus, retinitis 
pigmentosa, polyneuropathy, myopathy, and cerebellar hypotrophy/hypoplasia. A 
common marker for CDG is the underglycosylation of blood serum proteins such as 
transferrin. Depending on the type of CDG, the N-linked glycans differ in their structure 
and can be detected in carbohydrate-deficient transferrin (CDT). Interestingly, alcoholic 
liver disease (ALD) is accompanied by a N-glycosylation defect as well. Besides a similar 
pattern of CDT, certain forms of CDG and ALD share another common symptom: liver 
fibrosis. Chronic alcoholism is estimated to be responsible for 4% of global death and 
the liver being the primary site of ethanol metabolism is particularly affected. Despite 
the long history of CDT in ALD, glycosylation deficiency in ALD has not yet been 
characterized at the molecular level. 
So far, treatment of CDG is very restricted. In MPI-CDG, the mannose-phosphate 
isomerase is defective, an enzyme responsible for the conversion of fructose-6-
phosphate to mannose-6-phosphate, thereby providing mannose for the glycosylation 
machinery. A simple supplementation of nutrition with mannose was shown to 
attenuate the manifestations of MPI-CDG. 
In the first part of this thesis, we tested the potential of a cholesterol-lowering drug, 
Zaragozic acid A, to improve N-glycosylation in DPM1-CDG. DPM1 is a subunit of the 
dolichol-phosphate-mannose synthase which produces dolichol-phosphate-mannose, an 
important mannose donor for N-linked glycosylation. Zaragozic acid A inhibits an 
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enzyme at a bifurcation of the anabolic pathway common to dolichol and cholesterol 
synthesis. At this bifurcation, the metabolic flux either goes towards cholesterol or 
dolichol synthesis. By blocking the enzyme for cholesterol synthesis, N-linked protein 
glycosylation improved as observed by increased dolichol-phosphate-mannose levels, 
increased dolichol-phosphate levels, normalized dolichol- and N-linked oligosaccharide 
distribution. The restored dolichol-phosphate-mannose pool also resulted in better GPI-
anchor availability. We could compensate the lower dolichol-phopshate-mannose 
synthase activity by increasing substrate availability. Thus Zaragozic acid represents a 
possibility for drug treatment of DPM1-CDG. 
The second part of the thesis is focusing on ethanol-induced N-glycosylation deficiency. 
We studied the effect of ethanol on N-glycosylation in two hepatoma cell lines. The two 
cell lines VA-13 and HepaRG are distinct because they express alcohol dehydrogenase 
and cytochrome P450 2E1, respectively, which confers ethanol-metabolizing properties 
usually lost in cultured hepatocytes. We found lower dolichol levels in ethanol-treated 
cells. Moreover, the dolichol-linked oligosaccharide pattern was disturbed with a lower 
fraction of the final N-glycan precursor. The changes in glycosylation were accompanied 
by transcriptional changes. DPM1 was downregulated while RPN2 was upregulated. The 
transcriptional changes could be regulatory responses since we observed an increased 
DPM synthase activity despite the lower DPM1 transcription. 
In conclusion, we explored CDG and acquired deficiency in N-linked protein 
glycosylation by using a therapeutic approach to treat DPM1-CDG and by the 
characterization of N-glycosylation in an ethanol-induced glycosylation deficiency 
model. With this work we contributed to the search for treatment possibilities for CDG 
and promoted the understanding of ethanol-induced N-glycosylation deficiency. 
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ZUSAMMENFASSUNG 
Die Glykosylierung von Proteinen ist eine essentielle Proteinmodifikation, die in allen 
Domänen des Lebens vorkommt. Etwa 2% des humanen Genoms kodiert Proteine, die 
Teil der Glykosylierungsmaschinerie sind, und 50% der humanen Proteine sind 
glykosyliert. Die N-Glykosylierung von Proteinen beginnt im endoplasmatischen 
Retikulum, wo zuerst der N-Glykan Precursor schrittweise aufgebaut wird, indem 
einzelne Zuckerbausteine auf einem membran-gebundenen, reduzierten 
Polyprenolanker, dem Dolichol-phosphat, zusammengefügt werden. Der angefertigte N-
Glykan Precursor wird dann co- oder posttranslational vom Dolichol-phosphat auf 
spezifische Asparaginseitenketten von Zielproteinen übertragen. 
Aufgrund der Abundanz der N-Glykosylierung von menschlichen Proteinen in allen 
Zelltypen weisen vererbte N-Glykosylierungsdefekte ein multi-systemisches 
Krankheitsbild auf. Vererbte Glykosylierungsdefekte (CDG) beeinträchtigen meist die 
pränatale Entwicklung des Menschen. Die häufigsten CDG-Symptome sind Epilepsie, 
Hypotonie, Hyporeflexie, Strabismus, Retinitis pigmentosa, Polyneuropathie, Myopathie 
und Hypotrophie/Hypoplasie des Kleinhirns. Die Unterglykosylierung von 
Serumproteinen, wie z.B. Transferrin, wird als Marker für CDG benutzt. Abhängig vom 
CDG-Typ unterscheiden sich die N-Glykane auf Transferrin, weshalb verschiedene 
Formen von Desialotransferrin (CDT) detektiert werden können. Die alkoholische 
Leberkrankheit (ALD) wird interessanterweise von einem N-Glykosylierungsdefekt 
begleitet. Neben einem ähnlichen CDT-Bild zeigen gewisse CDG-Typen und ALD auch ein 
anderes gemeinsames Symptom: die Leberfibrose. Die Leber als primärer Ort des 
Ethanolabbaus ist besonders den Effekten des Alkoholismus betroffen. Obwohl der 
Zusammenhang zwischen CDT und ALD schon lange bekannt ist, wurde die 
Glykosylierungsdefizienz in ALD noch nicht vollständig auf molekularer Ebene 
charakterisiert. 
Die medikamentöse Behandlung von CDG ist sehr beschränkt. Ein Beispiel ist MPI-CDG, 
in der das Enzym, das für die Konversion von Fruktose-6-phosphat zu Mannose-6-
phosphat, defekt ist. Diese Reaktion ist wichtig, um Mannose für die 
Glykosylierungsreaktionen zur Verfügung zu stellen. Eine einfache Supplementierung 
der Nahrung mit Mannose ist in diesem Fall genug, um die Krankheitserscheinungen zu 
mildern. 
Zusammenfassung 
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Im ersten Teil dieser Dissertation untersuchten wir das Potenzial eines cholesterin-
senkenden Stoffs, Zaragozic acid A, die N-Glykosylierung in DPM1-CDG zu verbessern. 
DPM1 ist eine Untereinheit der Dolichol-phosphate-mannose Synthase, die als Komplex 
Dolichol-phosphate-mannose, einen wichtigen Mannose-donor für die N-Glykosylierung, 
produziert. Zaragozic acid A inhibiert ein Enzym an einer Verzweigung eines 
Synthesewegs, über den sowohl die Dolichol- als auch Cholesterinproduktion stattfindet. 
Bei der genannten Verzweigung geht der metabolische Fluss entweder in Richtung 
Dolichol- oder Cholesterinsynthese. Mit der Blockade des Enzyms, das die abzweigende 
Reaktion zur Cholesterinsynthese katalysiert, wurde die N-Glykosylierung verbessert, so 
dass erhöhtes Dolichol-phosphate und eine verbesserte Verteilung der dolichol- und N-
assozierten Oligosaccharide gemessen werden konnte. Ausserdem hatte die auf 
Normwerte erhöhte Dolichol-phosphat-mannose zur Folge, dass die Verfügbarkeit von 
GPI-Ankern verbessert wurde. Wir konnten also die reduzierte Aktivität der Dolichol-
phosphate-mannose Synthase mittels verbesserter Substratverfügbarkeit 
kompensieren. Daher stellt Zaragozic acid A ein potenzielles Medikament zur 
Behandlung von DPM1-CDG dar. 
Der zweite Teil der Dissertation fokussiert auf die ethanol-induzierte N-
Glykosylierungsdefizienz. Dazu haben wir den Effekt von Ethanol auf die N-
Glykosylierung in zwei Leberkrebszelllinien untersucht. Die VA-13 und die HepaRG 
Zelllinien sind gut dazu geeignet, weil sie im Gegensatz zu anderen kultivierten 
Leberzellen die Alkoholdehydrogenase und das Zytochrom P450 2E1 exprimieren, was 
die Metabolisierung von Ethanol ermöglicht. Wir konnten nach der Behandlung mit 
Ethanol niedrigeres Dolichol-phosphat sowie eine niedrigere Verfügbarkeit des N-
Glykan Precursors feststellen. Diese Glykosylierungsstörung wurde von 
transkriptionalen Veränderungen begleitet. DPM1 war runterreguliert während RPN2 
hochreguliert wurde. Diese Veränderungen der Transkription könnten regulatorische 
Mechanismen darstellen, da die DPM Synthase Aktivität erhöht war, obwohl die DPM1-
Untereinheit  transkriptional runterreguliert war. 
Zusammenfassend haben wir uns mit einem vererbten wie auch einem erworbenen N-
Glykosylierungsdefekt befasst. Wie haben einen therapeutischen Ansatz zur Milderung 
des N-Glykosylierungsdefekts in DPM1-CDG Fibroblasten erfoglsversprechend getestet 
und den ethanol-induzierten N-Glykosylierungsdefekt in zwei Leberzelllinien 
charakterisiert. 
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ABBREVIATIONS 
 
9-ADM 9-anthryldiazomethane 
ADH Alcohol dehydrogenase 
ALD Alcoholic liver disease 
ALG Asparagine-linked glycosylation 
CDG Congenital Disorders of Glycosylation 
CDT Carbohydrate-deficient transferrin 
CYP2E1 Cytochrome P450 2E1 
DLO Dolichol-linked oligosaccharide 
DMSO Dimethyl sulfoxide 
DNA Desoxyribonucleic acid 
Dol Dolichol 
Dol-P Dolichol-phosphate 
Dol-PP Dolichol-pyrophosphate 
DPM Dolichol-phosphate mannose (synthase) 
ER Endoplasmic Reticulum 
ERAD Endoplasmic reticulum-associated degradation 
FBS Fetal bovine serum 
Gal Galactose 
GDP Guanosine diphosphate 
Glc Glucose 
GlcNAc N-acetlyglucosamine 
GPI Glycophosphatidylinositol 
HMG-CoA 3-hydroxy-3-methyl-glutaryl-coenzyme A 
HPLC High performance liquid chromatography 
IEF Isoelectric focusing 
LLO Lipid-linked oligosaccharide 
Man Mannose 
MPI Mannose-phosphate isomerase 
Abbreviations 
   
14 
 
mRNA Messenger RNA 
NAD(H) β-Nicotineamide adenine dinucleotide (reduced) 
NLO N-linked oligosaccharide 
OST Oligosaccharyltransferase 
PCR Polymerase chain reaction 
PMM Phosphomannomutase 
RNA Ribonucleic acid 
UDP Uridine disphosphate 
ZGA Zaragozic acid A 
Fuc Fucose 
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INTRODUCTION 
Post-translational modifications of proteins are crucial for maintaining proper 
functioning of cells and whole organisms. Among the most important protein 
modifications in animals are phosphorylation, lipid conjugation, ubiquitination, and 
glycosylation. Phosphorylation is essential in many cellular processes and mostly 
regulates activity of the modified proteins (Hunter, 2000) while ubiquitination marks 
proteins for the major pathway of proteasomal protein degradation (Hochstrasser, 
2009). Lipid modifications serve as membrane anchors to restrict proteins to the ER, 
Golgi apparatus, or the plasma membrane (Nadolski and Linder, 2007). Glycosylation is 
the most frequent protein and lipid modification which is apparent when looking at the 
complex and dense layer of glycans that covers the surface of all living organisms 
including viruses (Larkin and Imperiali, 2011; Spiro, 2002). About 2% of the human 
genes are involved in glycan formation as enzymes, transporters, or cofactors (Freeze et 
al., 2012; Varki et al., 2008). Glycans are the most diverse and versatile biomolecules in 
terms of target substrates, chemical linkages, and non-linear branching. In humans, 50% 
of all proteins are glycosylated underlining the significance of protein glycosylation. 
However, defining functions of glycosylation is difficult due to its inherent complexity 
and requirement for advanced technology and methodology. The process of 
glycosylation describes the attachment of a single saccharide or polysaccharide from a 
donor substrate to an acceptor substrate. The donor substrate consists of a sugar 
building block activated by a carrier via phospho-diester or phospho-ester bond. Donor 
as well as the acceptor substrates are recognized by enzymes termed 
glycosyltransferases which attach the sugar building block to the acceptor substrate in a 
linkage-specific manner. 
 
Monosaccharides: Building blocks of glycosylation 
Nine different monosaccharides are used to produce glycoconjugates in mammals 
(Figure 1). Despite the close to infinite number of possibilities to combine these 
monosaccharides due to linkage and branching features of sugars, relatively few 
combinations do actually exist. This can be explained by the specificity of the known 
glycosyltransferases which function with donor and acceptor substrate specificity as 
Introduction 
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well as linkage specificity. Therefore, unlimited and functional glycan diversity would 
require a huge number of glycosyltransferases which themselves would need regulation.  
Another level of complexity is added by modifications of glycans. Sulfation, acetylation, 
and methylation and epimerization of GlcA to iduronic acid can occur on the conjugated 
glycan (Silbert and Sugumaran, 2002; Varki et al., 2009). These glycan modifications 
require activated substrates, i.e. 3′-phosphoadenyl-5′-phosphosulfate for sulfation, 
acetyl-CoA for acetylation, and S-adenosylmethionine for methylation. Activated 
substrates are produced in the cytoplasm and therefore depend on membrane 
transporters to reach the ER-Golgi pathway. 
 
Figure 1 Structural representations of the nine monosaccharides used in mammalian 
glycosylation. The names of the sugars are indicated below the structure including the 
abbreviations used in this thesis. (adapted from (Varki et al., 2008)) 
 
The complexity of glycans is major challenge for structural elucidation even with the 
most advanced approaches using mass spectrometry (Kolarich et al., 2013; Mechref et 
al., 2012; Zaia, 2010; Zaia, 2013). 
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 Major glycan classes in eukaryotic cells 
The major classes of glycosylation in animal cells take place in the ER and the Golgi 
apparatus (Figure 2). O-GlcNAc (Comer and Hart, 2000; Guinez et al., 2005; Hart and 
Akimoto, 2009), O-Glc (Whitworth et al., 2010), and O-Fuc (Moloney et al., 2000; Panin 
et al., 2002) modifications can occur in the ER as well as in the nucleus and cytoplasm 
representing exceptions and are not within the scope of this thesis. Every glycan class 
features an individual glycan core that can be elongated and modified. 
 N-glycans, O-glycans, and glycosaminoglycans (GAG) are protein-linked whereas GPI 
anchors and glycosphingolipids represent lipid-linked modes of glycosylation. GPI 
anchors themselves are protein modifications and are conjugated to the C-terminus of 
target proteins in the ER. 
 
Figure 2 Glycan classes and their maturation in the ER-Golgi pathway. The initial steps of N-
glycosylation, O-glycosylation, glycosaminoglycan synthesis, GPI anchor formation, and 
glycosphingolipid synthesis occur in the ER. Elongation and maturation processes take place in 
the Golgi complex. (from (Varki et al., 2008)) 
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N-linked protein glycosylation 
The N-linked glycan core originates from an N-glycan precursor in the ER (Aebi, 2013). 
There, N-linked protein glycosylation occurs on Asn residues co- or post-translationally. 
When a protein with an N-glycan consensus sequence Asn-X-Ser/Thr (X can be any 
amino acid except Pro) is translated into the ER, an oligosaccharide structure termed N-
glycan precursor is transferred from dolichol-pyrophosphate (Dol-PP) to the Asn of the 
consensus site (Marshall, 1974). The N-glycan thereafter can assist in the folding of the 
modified protein in the ER. After trimming the original N-glycan, the N-glycosylated 
protein follows the secretory pathway to the Golgi apparatus where further trimming 
and subsequent addition of various monosaccharides can occur. Furthermore, glycans 
can undergo a maturation process involving chemical modifications. Finally, the 
glycosylated protein is secreted or transported to its target membrane. 
 
Types of N-linked glycans 
Three types of N-linked glycans are distinguished: High mannose type, complex type, 
and hybrid type (Figure 3). They all originate from the N-glycan precursor after passing 
through the glycosylation machinery in the ER and Golgi complex. 
 
Figure 3 N-glycan classes. The three N-glycan classes share a common core (Man3GlcNAc2). 
Blue squares represent GlcNAc, green circles Man, yellow circles Gal, purple diamonds sialic 
acid, and red triangle Fuc. (from (Varki et al., 2008)) 
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Biosynthesis of the N-linked glycan precursor in the Endoplasmic Reticulum 
The first part of N-linked protein glycosylation requires the assembly of the N-glycan 
precursor Glc3Man9GlcNAc2 on Dol-PP, a lipid carrier residing in the ER membrane 
(Figure 4). The formation of dolichol (Dol) occurs in the mevalonate pathway and is 
described and discussed in detail in the section “Regulation of Dolichol-linked 
glycosylation” (Ramachandran and Melnykovych, 1986). The substrate for the initial 
glycosyltransferases is dolichol-P (Dol-P) that is supplied by dolichol kinase (DK) 
phosphorylating Dol (red rectangle in Fig. 4). The precursor is built by the addition of 
single sugar blocks in a sequence-, linkage-, and conformation-specific manner. The first 
seven steps occur at the outer leaflet of the ER. Two GlcNAc (blue squares) are 
sequentially added to Dol-P by DPGAT1 and ALG13/14, respectively. Both enzymes 
require UDP-GlcNAc as a substrate but DPGAT1 links P-GlcNAc to Dol-P resulting in 
GlcNAc-PP-Dol and UMP. ALG13/14 produces GlcNAc2-PP-Dol and UDP. ALG1 catalyzes 
the addition of the first Man residues (green circles) from GDP-Man to GlcNAc2-PP-Dol. 
Thereafter, ALG2 adds two Man from GDP-Man to ManGlcNAc2-PP-Dol.  The last two 
steps at the outer leaflet of the ER are catalyzed by ALG11 which adds two Man to - 
Man3GlcNAc2-PP-Dol resulting in the intermediate Dol-linked oligosaccharide (DLO) 
Man5GlcNAc2-PP-Dol. RFT1 flips this DLO across the ER membrane into the lumen by a 
yet unresolved mechanism. Four further Man are added by the indicated enzymes using 
Dol-P-Man as source of Man. Notably, ALG9 recognizes both Man6GlcNAc2-PP-Dol as well 
as Man8GlcNAc2-PP-Dol as substrates for mannosylation. Three Glc sugars are 
transferred from Dol-P-Glc to the DLO by the sequential action of ALG6, ALG8, and 
ALG10. Finally, the completed N-glycan precursor Glc3Man9GlcNAc2 (Figure 4) is 
transferred en bloc from Dol-PP to the amide group of Asn side chains in the consensus 
sequence Asn-X-Ser/Thr by the oligosaccharyl-transferase complex (OST). Site 
occupancy analyses of different glycoproteins revealed a preference for N-X-T over N-X-
S sites (Gavel and von Heijne, 1990). Dol-PP is recycled by dephosophorylation to Dol-P 
and subsequent flipping to the cytosolic leaflet (Cantagrel and Lefeber, 2011; 
Ramachandran and Melnykovych, 1986; Rush et al., 2008). Recycling critically 
contributes to Dol-P availability but the molecular details of Dol-P recycling remain 
elusive. 
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Figure 4 Biosynthesis of dolichol-linked oligosaccharides (DLO) dolichol-activated 
monosaccharides. The N-glycan precursor is assembled by the stepwise addition of 
monosaccharides. On the cytosolic leaflet of the ER, two GlcNAc and five Man are transferred to 
Dol-P using nucleotide-activated monosaccharides as substrates. Dol-PP-GlcNAc2Man5 is flipped 
into the ER lumen where the DLO is extended with four Man and three Glc by glycosyl-
transferases using Dol-P-activated monosaccharides as substrates. The finished Dol-PP-linked 
N-glycan precursor can then be transferred to a target protein. Red labels indicate proteins 
associated with congenital disorders of glycosylation. Blue labels indicate proteins that have not 
been found in congenital disorders of glycosylation so far. (adapted from (Haeuptle and Hennet, 
2009)) 
 
Processing of the N-linked glycan 
After transfer to target proteins, the N-linked glycan can assist the protein in folding 
properly. This cyclic process is termed ER quality control and involves the chaperone 
proteins calnexin and calreticulin which can recognize N-glycans on unfolded proteins 
(Williams, 2006). Immediately after the glycan transfer, α-glucosidase I removes the 
terminal α1–2-linked Glc and glucosidase II then removes the two α1-3-linked Glc 
sugars. The resulting oligosaccharide is taking part in the ER folding quality control. 
Iterative reglucosylation by UGGT1 and deglucosylation during the folding process 
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ensure retention of improperly folded proteins in the so-called calnexin/calreticulin 
cycle (see section “ER quality control of protein folding” and (Helenius and Aebi, 2004)). 
Many de-glucosylated glycans on properly folded proteins are processed by ER α-
mannosidase I before exiting the ER which removes the α1-2-linked Man from the 
central branch of the glycan resulting in a Man8GlcNAc2-Asn isomer. Most glycans exit 
the ER with eight or nine Man residues but some escape the quality control processing 
and can carry a terminal Glc when entering the Golgi apparatus. 
 
Figure 5 Schematic structure of the N-linked glycan 
precursor. It consists of two GlcNAc (blue squares), 
nine Man (green circles), and three Glc (blue circles). 
The residues are labeled alphabetically for cross-
referencing. Linkage specificities are indicated at the 
connections between linked sugars. 
In the Golgi, incompletely processed GlcMan8GlcNAc2-Asn is acted on by endo-α-
mannosidase which cleaves the disaccharide Glcα1-3Man off the glycan resulting in a 
Man8GlcNAc2-Asn different from the one produced by ER α-mannosidase I. Further 
trimming occurs by α1-2 mannosidases IA, IB, and IC in the cis-Golgi resulting the 
important intermediate glycan Man5GlcNAc2-Asn. From Man5GlcNAc2-Asn, hybrid and 
complex N-glycans can arise from remodeling but some of these structures escape 
remodeling. Glycans that evade these early de-mannosylation steps will not be further 
processed and together with un-processed GlcNAc2Man5-Asn represent oligomannose 
glycans of the type Man5-9GlcNAc2-Asn on mature glycoproteins. Most glycoproteins 
carry some unprocessed, oligomannose glycans. 
The initial step in hybrid and complex glycan formation occurs in the medial-Golgi and is 
catalyzed by the β1-2 N-acetylglucosaminyltransferase GnT-I which adds an GlcNAc to 
position C2 of the α1-3-linked Man in the core of Man5GlcNAc2-Asn (cp. Figure 4). Only 
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after GnT-I action, the glycan is recognized by α-mannosidase II which removes 
terminally attached α1-3 and α1-6 Man. The resulting GlcNAcMan3GlcNAc2-Asn is 
further modified by GnT-II giving rise to the precursor of all biantennary, complex N-
glycans. If α-mannosidase II is not acting on the glycan, the result are hybrid N-glycans 
still carrying the unmodified terminal α1-3 and α1-6 Man in the mature glycoprotein. 
From glycans that are incompletely processed by α-mannosidase II, another hybrid of 
the type GlcNAcMan4GlcNAc2-Asn emerges. Another enzyme, α-mannosidase IIx, also 
cleaves GlcNAcMan5GlcNAc2-Asn generated by GlcNAcT-I. Mouse double knockouts 
missing α-mannosidase II and IIx totally lack complex N-glycans (Moremen, 2002). 
Branching of complex N-glycans starts with GlcNAcylation of Man giving rise to complex 
glycans with up to four branches in mammals and five branches in fish and birds. 
In the trans-Golgi, hybrid and branched N-glycans undergo further modifications which 
is referred to as maturation. Three types of maturation can occur: sugar additions to the 
core glycan, sugar additions to elongate branching GlcNAc, and capping of the elongated 
branches. In vertebrates, fucosylation by FucT-VIII is the most common core 
modification. Very rarely, modification of the core with GlcNAc can occur. Elongation 
typically takes place by initial addition of β-linked N-acetyllactosamine to the initiating 
GlcNAc. If lactose is added to the C4 position of the initiating GlcNAc, the most frequent -
Galβ1-4GlcNAc- repeat termed type-2 N-acetyllactosamine is produced.  If lactose is 
linked to position C3, the less frequent type-1 N-acetyllactosamine, -Galβ1-3GlcNAc-, 
arises. Further alternate elongation by GlcNAc and Gal yield a type-2 or type-1 “LacNAc” 
sequence. The last and most important modification is the “capping” or “decorating” of 
glycan branches. Capping encompasses the addition of terminal sialic acid, fucose, 
galactose, GlcNAc, and sulfate. Interestingly, such capping structures are shared by N- 
and O-glycans as well as glycolipids. The α-linkage of the terminal sugars contrasts with 
the common β-linkages within the branches and confers better accessibility for lectins 
or antibodies due to the protrusion away from the β-linked ribbon-like branches. 
 
Functions of N-linked protein glycosylation 
The most prominent and obvious functions of N-linked protein glycosylation are linked 
to the early steps of protein glycosylation. Early functions of N-linked glycans 
encompass recruitment of molecular chaperones for facilitated protein folding, proper 
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processing and targeting of the N-glycosylated protein, and enhancing solubility and 
protein stability (Hebert et al., 1997; Hurtley and Helenius, 1989; Klausner and Sitia, 
1990; Olden et al., 1982). In addition to structural and regulatory properties, glycans are 
involved in more specific recognition events which are dependent on carbohydrate-
binding proteins, so-called lectins. With increasing complexity of the N-glycans in the 
elongation and maturation process, less global but more specific functions of the glycan 
unfold. Functions of glycans which require specific recognition involve carbohydrate-
binding proteins termed lectins. Moreover, glycosaminoglycan-binding proteins and 
carbohydrate-binding antibodies are defined classes of glycan-binding proteins. 
Different types of lectins are defined based on their sequence and structural homology.  
Generally, a function of a specific glycan for a specific glycoprotein is difficult to assess. 
Moreover, the same glycan structure can have different functions depending on the 
protein it is attached to, on the location within an organism, and on the developmental 
state of an organism or life cycle of a single cell (Varki, 1993; Varki et al., 2008). 
Functions of glycans are difficult to address especially since an introduced defect in 
isolated cells often may or may not show a marked phenotype but still may have 
catastrophic consequences on the whole, functional organism. Below, some functions of 
N-glycans are presented. More extensive discussion of N-glyan functions are described 
elsewhere (Varki, 1993; Varki et al., 2008). 
 
Quality control of protein folding in the Endoplasmic Reticulum 
Folding and subsequent processing and secretion of some proteins is highly dependent 
on N-linked glycans. Notably, blocked N-glycosylation can result in different outcomes 
ranging from partial loss of folding and impaired secretion efficiency to temperature 
sensitivity of the affected proteins (Helenius, 1994). The importance of N-glycosylation 
for folding usually correlates with the number of N-glycosylation sites in a protein 
(Helenius and Aebi, 2004). The effects of a glycan on protein folding can be of 
biophysical nature by restricting the conformational space of the polypeptide chain, by 
promoting the formation of β-turns through the interaction of the N-acetyl groups of the 
first GlcNAc residues with the polypeptide chain, or by just globally enhancing solubility 
of folding peptide chains (Imberty and Perez, 1995; Imperiali and O'Connor, 1999; 
O'Connor and Imperiali, 1996; Wormald and Dwek, 1999). The indirect effects of N-
glycans on protein folding are dependent on a complex machinery of 
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glucosyltransferase, glucosidase, lectins (carbohydrate-binding proteins), and 
associated factors as for instance thiol-disulfide oxidoreductases. 
The central enzyme of protein folding quality control is the glucosyl-transferase UGGT1. 
It can recognize and bind hydrophobic patches of unfolded proteins and re-glucosylate 
Man9GlcNAc2-Asn. As long as an N-glycosylated protein remains unfolded, the 
oligosaccharide is subjected to iterative de- and re-glucosylation by glucosidase and 
UGGT1, respectively (Suh et al., 1989). Unfolded proteins carrying monoglucosylated 
glycans enter the so-called calnexin/calreticulin cycle and are bound by calnexin 
(membrane bound) or calreticulin (soluble ER protein) which retain the protein in the 
ER (Hammond and Helenius, 1993; Hammond and Helenius, 1994; Peterson et al., 
1995). Binding to calcium-dependent lectins calnexin or calreticulin prevents unfolded 
proteins from aggregation or premature degradation thereby assisting in folding 
together with other chaperones and protein disulfide isomerases (e.g. BiP, Grp94, 
ERp57, PDI). Monoglucosylated Man structures on unfolded proteins also interacts with 
degradation enhancing α-mannosidase-like protein (EDEM) targeting terminally 
misfolded proteins to proteasomal degradation. 
 
Endoplasmic Reticulum-associated degradation (ERAD)  
Degradation of proteins from the ER require translocation to the cytosol due to the 
cytoplasmic location of the proteasomal degradation machinery. Terminally misfolded 
proteins from the ER are recognized, targeted to the ER membrane, and 
retrotranslocated to the cytosol in a multi-step process. Numerous ERAD factors act on 
target peptides which function in substrate recognition, targeting, extraction from the 
ER, ubiquitination, and finally degradation (Helenius and Aebi, 2004; Nakatsukasa and 
Brodsky, 2008). 
The basis of ERAD is given by the competition for unfolded, N-glycosylated proteins by 
calnexin/calreticulin and binding of EDEM. This competition depends on N-glycan 
trimming and is time-dependent. Immediate removal of the terminal Glc sugars after the 
transfer of the glycan precursor on a target protein ensures entering into the 
calnexin/calreticulin cycle for assisted folding. The longer the time an unfolded protein 
spends in the ER, the more likely it will be degraded via ERAD. This mechanism is 
possible through the trimming enzyme mannosidase I which removes the terminal Man 
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from the mid branch of the N-linked glycan to yield Man8GlcNAc2-Asn. Mannosidase I 
seems to act as a timer due to its relative inefficiency to act on N-glycans. Once 
mannosidase I action is complete, unfolded target proteins are recognized by EDEM 30-
90 minutes after translation. The recognition by EDEM depends on a bipartite signal 
consisting of an N-glycan trimmed by mannosidase I and an unfolded peptide (Xie et al., 
2009). Interestingly, Man removal slows down the calnexin/calreticulin cycle because of 
decreased efficiency of glucosidase II and UGGT1 upon mannosidase I action. Other 
mannosidases cleaving the terminal Man from the other two branches have been found 
but their roles in ERAD are not yet fully understood. 
 
Intracellular transport and targeting to lysosomes 
Protein sorting and targeting is often based on signals within the amino acid sequence of 
a protein. Specific glycan structures can target proteins to different compartments of a 
cell as well. Targeting to the Golgi complex for instance is achieved by P-type lectins that 
bind mannose-6-phosphate (M6P). Two different M6P receptors exist and both bind to 
M6P with high affinity (Ghosh et al., 2003; Munier-Lehmann et al., 1996). 
Lysosomal enzymes carry oligomannose N-glycans with one or two phosphate 
modifications on the C6 position of various Man. Selected Man are not directly 
phosphorylated by kinases but are acted on by UDP-GlcNAc-dependent GlcNAc-1-
phosphotransferase (GlcNAc-P-T) (Gelfman et al., 2007; Ghosh and Kornfeld, 2004). The 
resulting GlcNAcα1-P-6-Manα1-(N-glycan)-Asn is then processed by a Golgi-resident 
enzyme removing GlcNAc and uncovering the M6P recognition marker. The generation 
of the M6P recognition marker must be very specific in order to deliver lysosomal 
enzymes reliably to the lysosome. Since GlcNAc-P-T target proteins do not share any 
amino acid sequence similarity, substrate specificity is given by secondary and tertiary 
structures of target proteins. As few as two lysine residues in proper orientation 
towards each other and towards the oligomannose N-glycan are sufficient to be 
recognized by GlcNAc-P-T. Additional amino acid residues or recognition domains can 
enhance interaction with GlcNAc-P-T (Braulke et al., 2008). 
The M6P receptors mainly localize to the trans-Golgi network and late endosomes from 
where they cycle between early sorting endosomes, recycling endosomes, and the cell 
membrane. M6P receptor trafficking is achieved by sorting signals in their cytoplasmic 
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tails. Once a lysosomal protein is recognized by a receptor in the trans-Golgi network, 
the receptor-protein complex is recruited to clathrin-coated pits. Arrival at the early 
endosomes triggers the release of the lysosomal protein from the M6P receptors due to 
the decrease in pH. Interestingly, accidentally secreted lysosomal proteins can be 
captured by one of the two receptors at the cell surface and internalized by clathrin-
mediated endocytosis. 
 
Hepatic asialoglycoprotein receptor 
The hepatic asialoglycoprotein receptor, ASGPR, was the first C-type (Ca2+ dependent) 
lectin to be discovered (Irie and Tavassoli, 1986; Tavassoli, 1985). ASPGR assists in the 
clearance of blood proteins by binding desialylated blood proteins. Studies 
demonstrated a preference of ASPGR for terminal GalNAc residues but also binding to 
Gal. Many pituitary protein hormones and parasite-derived proteins contain terminal 
GalNAc residues potentially recognized by ASPGR. Protein stability mediated by glycans 
is therefore not only a direct effect of enhanced solubility or protection against 
proteases but also by regulatory possibilities by marking desialylated proteins for 
clearance. This mechanism can also be observed in immune cells that recognize glycans 
as virulent factors and mediate endocytosis. 
 
N-glycans and integrin functions 
Integrins are plasma membrane proteins with a lectin portion in the extracellular space 
and function as adhesion proteins binding the extracellular matrix as well as in 
transducing signals from the extracellular space into the cell (Gu et al., 2012; Hynes, 
2002). As a consequence, aberrant integrin function has been associated with tumor 
invasion (Bellis, 2004; Dennis et al., 2002). Changes in N-glycosylation of integrins were 
shown to potentially regulate cell adhesion (Isaji et al., 2010). The N-
acetylglucosaminyltransferase III (GnT-III) adds the “bi-secting” GlcNAc to the core Man 
(c, Figure 4) of the N-linked glycan thereby suppressing further branching of the glycan. 
Overexpression of GnT-III resulted in decreased branching of integrin N-glycans and 
inhibition of integrin-mediated spreading and migration of cancer cells. Conversely, 
GnT-III knockdown resulted in more N-glycan branching and increased cell migration. 
Accordingly, diverse cancer cell lines were reported to have increased glycan branching 
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(Blomme et al., 2012a; Blomme et al., 2012b; Blomme et al., 2013; Blomme et al., 2009; 
Dennis, 1991). 
 
Congenital disorders in N-linked glycosylation 
Congenital disorders of glycosylation (CDG) are a rapidly growing family of diseases 
affecting different glycosylation pathways (Eklund and Freeze, 2006; Freeze, 2007; 
Grunewald, 2007; Jaeken, 2013). Genetic defects can affect all classes of glycosylation 
presently adding up to more than 80 affected genes. The most frequently affected 
pathway in CDG is N-linked glycosylation (Freeze and Aebi, 2005; Haeuptle and Hennet, 
2009). Among these CDG, defects in the assembly of the N-glycan precursor in the ER 
(Figure 4) and defects in N-glycan maturation and processing in the Golgi complex are 
distinguished. 
Individuals with CDG typically show diverse dysfunctions in several organ systems 
reflecting the importance and abundance of functions of glycosylation. Most 
prominently, patients show strong neurological defects or at least a neurological 
component among the symptoms. The most frequent symptoms are psychomotor 
retardation, epilepsy, hypotonia, hyporeflexia, strabismus, retinitis pigmentosa, 
polyneuropathy, myopathy, and cerebellar hypotrophy/hypoplasia. This broad range of 
symptoms hampers recognition of CDG and likely lead to under-diagnosis. Additionally, 
the severity of CDG often leads to death in early infancy making diagnosis more difficult 
(Funke et al., 2013). Decreased occupancy of N-glycosylation sites are a common feature 
of most CDG. Therefore, diagnosis of CDG is done by carbohydrate-deficient transferrin 
(CDT) analysis using isoelectric focusing or mass spectrometry-based approaches. 
Transferrin is a blood serum protein with two Fe(III) binding sites produced and 
secreted by the liver. Serum transferrin takes part in iron homeostasis by binding Fe(III) 
in the blood and transporting it to target sites where it is absorbed by receptor-
mediated endocytosis. Reaching early endosomes, the drop in pH triggers the release of 
iron without breaking the association of transferrin to its receptor. After iron release, 
receptor-bound transferrin is recycled into the blood stream where it can again bind 
iron. Transferrin normally carries two bi-antennary N-glycans and therefore has four 
capping sialic acids in total. Besides this so-called tetrasialo-transferrin, 10-15% of 
transferrin carry one or two tri-antennary N-glycans giving rise to pentasialo- and 
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hexasialo-transferrin. CDG can be distinguished from other metabolic diseases with 
similar manifestations by assessing the glycoform distribution of transferrin. Blood 
plasma from CDG patients contains hypoglycosylated transferrin. Deficiencies in the 
early steps of the glycan precursor assembly (former CDG-I type) on Dol result in 
increased occurrence of disialo- and asialo-transferrin while defects in later stage of N-
glycosylation (former CDG-II type) result in a higher proportion of trisialo- and 
monosialo-transferrin. Notably, a missing hypoglycosylation phenotype of transferrin 
does not rule out CDG. In adults, a hypoglycosylation phenotype can arise from alcohol 
abuse that results in perturbed N-glycosylation in the liver leading to CDT. With the 
discovery of vesicular transport defects impairing glycosylation, the former distinction 
between CDG-I and CDG-II types was replaced by the name of the deficient gene instead, 
e.g. CDG-ALG6 (Jaeken et al., 2008). 
The identification and characterization of CDG of N-linked glycosylation has shown that 
basically every single gene along the pathway can be affected (Figure 4). However, the 
severity of a given CDG at the systemic level is difficult to predict.  A totally dysfunctional 
enzyme is likely to lead to embryonic death and observed gene defects in CDG seem to 
retain residual enzyme activity of the affected protein. Yeast models have played a 
pivotal role in identifying gene defects in CDG (Aebi and Hennet, 2001). Typically, a 
patient diagnosed with CDG based on CDT analysis has an aberrant DLO pattern that can 
be defined from skin fibroblasts. Comparison of a specific accumulation of DLO with 
yeast mutants is used to identify affected genes. Cloning of the human gene and 
complementation analysis in the yeast mutant can confirm the putative CDG. The 
development of whole-exome sequencing methods has enabled screening of patients 
with psychomotor retardation for mutated genes and recently has led to the 
identification of new forms of CDG (Freeze et al., 2012; Hennet, 2012; Matthijs et al., 
2013).  
Recently, a novel type of CDG affecting the biosynthesis of Dol-P has emerged.  Dol is not 
only involved in N-glycosylation but also in O-mannosylation, C-mannosylation and GPI-
anchor biosynthesis. This group of CDG is discussed in the section “Regulation of Dol-
linked glycosylation” (Welti, 2013). 
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Alcoholic liver disease and N-linked glycosylation deficiency 
Alcoholic liver disease (ALD) is a consequence of chronic and excessive alcohol intake. 
Since the liver is the primary site of ethanol degradation, side-effects of ethanol and its 
degradation products acetaldehyde and acetate along with “by-products” like excess 
NADH and reactive oxygen species have considerable impact on liver function. An 
estimated 50% of liver cirrhosis with lethal outcome is attributable to alcohol 
consumption (WHO, 2011). 
A major cause of ethanol-induced liver injury is oxidative stress exerted by the products 
of ethanol degradation. Many symptoms of liver injury have been described involving 
disruption of various liver functions. Transcription factors are activated (NF-κB, Nrf-2, 
AP-1) and the expression of antioxidant enzymes (glutathione S-transferase, catalase, 
heme oxigenase-1) is upregulated (Dey and Cederbaum, 2006). Moreover, ethanol 
impairs the ubiquitin-proteasome system, leading to the promotion of apoptosis through 
pathways depending on the degradation of inhibitory factors (Donohue et al., 2007). 
Degradation of ethanol occurs in two major pathways. Alcohol dehydrogenase (ADH) is 
constitutively expressed in hepatocytes and converts ethanol to acetaldehyde under 
expenditure of NAD. The second pathway depends on the inducible cytochrome P450 
system, originally discovered as microsomal ethanol-oxidizing system and occurs in the 
smooth ER. Many isoforms of these microsomal cytochromes exist but only cytochrome 
P450 II E1 (CYP2E1) is induced upon ethanol consumption (Koivisto et al., 1996; Oneta 
et al., 2002; Salmela et al., 1998; Takahashi et al., 1993). Acetaldehyde produced by ADH 
and CYP2E1 is further oxidized by acetaldehyde dehydrogenase to yield acetate. Acetate 
can be fueled into the citric acid cycle or used for the biosynthesis of a variety of 
carbohydrate-based molecules (Berg et al., 2007). 
Initial effects of chronic alcohol abuse are of metabolic nature and result in inhibition of 
glycolysis due to excess reductive compound NADH. Glycolysis is a major pathway for 
energy production in which Glc yields 2 molecules of ATP, 2 molecules of NADH, and 2 
molecules of pyruvate. Pyruvate can then be fueled into the citric acid cycle which 
produces 15 ATP molecules per Glc. The conversion of ethanol to acetaldehyde and 
eventually acetate produces 2 molecules of NADH. Acetate is used as a substrate for the 
citric acid cycle. Excess NADH from ethanol metabolism from chronic alcohol abuse 
induces a negative feedback loop and disrupts the chemical equilibrium of reactions in 
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glycolysis and the citric acid cycle. Additionally, NADH accumulation inhibits β-oxidation 
of lipids thus inhibiting lipid breakdown. As a consequence, fatty acid synthesis is 
prompted and lipid storage marks the beginning of fatty liver disease (Sozio and Crabb, 
2008). Sustained ethanol abuse leads to chronic inflammation of the liver eventually 
leading to fibrosis and cirrhosis. 
Protein glycosylation deficiency in the context of ALD is a poorly investigated area 
despite the fact that ethanol uptake correlates with carbohydrate-deficient blood 
proteins (Stibler, 1991). The blood serum protein transferrin for instance is 
carbohydrate-deficient in both, CDG and alcoholism. Interestingly, liver fibrosis is not 
only frequent in ALD but also in some forms of CDG (Jaeken et al., 1998; Pelletier et al., 
1986). The detection of carbohydrate-deficient transferrin has been widely used as a 
tool to detect alcoholism and CDG (Jaeken and Matthijs, 2007). The detection of 
carbohydrate-deficient transferrin is based on the detection of the different glycoforms. 
Transferrin contains two consensus sequences for N-linked glycosylation. Potentially 
each N-linked glycan can carry three sialic acids, each conferring a negative charge to 
the protein. Isoelectric focusing separates the distinct glycoforms according to their 
isoelectric point that is dependent on the number of carboxyl functional groups. In 
healthy individuals, the tetrasialo-transferrin is predominant. Pentasialo-, trisialo-, and 
disialo-transferrin can be detected to a lower extent. The glycoform distribution is 
shifted in individuals suffering from chronic alcoholism. Still, the tetrasialo-transferrin is 
the predominant form but more disialo-transferrin can be detected. In addition, 
monosialo- and asialo-transferrin are present (Helander et al., 2004; Stibler, 1991). A 
commonly used model is the human hepatocellular carcinoma cell line HepG2 which was 
isolated from a child and shows active plasma protein secretion (Knowles et al., 1980). 
HepG2 cells treated with 50-100 mM ethanol were shown to have a decreased 
transcription of the alpha-2,6-sialyltransferase (2,6-ST). This transferase is responsible 
for the sialylation of transferrin at the ends of the attached sugar chains. Lower 2,6-ST 
and increased activity of plasma and plasma membrane sialidases were observed in the 
liver from chronically ethanol-fed rats and humans (Cottalasso et al., 1996; Ghosh et al., 
1993; Xin et al., 1995). Additionally, the 2,6-ST mRNA is destabilized by a 3’-
untranslated region-specific binding protein as could be demonstrated by depletion 
experiments (Garige et al., 2006; Garige et al., 2005; Rao and Lakshman, 1997; Rao and 
Lakshman, 1999). Notably, the downregulation of 2,6-ST does not necessarily need to be 
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the only cause of carbohydrate-deficient transferrin. Furthermore, lower GlcNAc 
transferase activity was found in livers of ethanol-fed rats (Xin et al., 1995). As 
illustrated in Figure 4, several intermediates might be affected as well, potentially 
leading to asialo-transferrin or a shift in glycoforms. In CDG patients suffering from very 
severe forms the disorder, the occupancy of the second N-glycosylation site can be 
reduced to 41%. In contrast, the occupancy of the first site was maximally reduced to 
71%. CDT from chronic alcohol abuse exhibits a site occupancy of more than 90% for 
both N-glycosylation sites (Hülsmeier et al., 2007). The presence of sialic acid-deficient 
transferrin was mainly attributed to the loss of an entire oligosaccharide in another 
study (Peter et al., 1998). Another defect induced by chronic alcohol treatment is an 
impaired synthesis of Dol and Dol-P (Cottalasso et al., 1998; Cottalasso et al., 1996).  
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Abstract 
The majority of Congenital Disorders of Glycosylation (CDG) are caused by defects of 
dolichol (Dol)-linked oligosaccharide assembly, which lead to under-occupancy of N-
glycosylation sites. Most mutations encountered in CDG are hypomorphic, thus leaving 
residual activity to the affected biosynthetic enzymes. We hypothesized that increased 
cellular levels of Dol-linked substrates might compensate for the low biosynthetic 
activity and thereby improve the output of protein N-glycosylation in CDG. To this end, 
we have investigated the potential of the squalene synthase inhibitor zaragozic acid to 
redirect the flow of the poly-isoprene pathway towards Dol by lowering cholesterol 
biosynthesis. The addition of zaragozic acid to CDG fibroblasts with a Dol-P-Man 
synthase defect led to the formation of longer Dol-P species and to increased Dol-P-Man 
levels. This treatment was shown to decrease the pathologic accumulation of incomplete 
Dol-PP-GlcNAc2Man5 in Dol-P-Man synthase deficient fibroblasts. Zaragozic acid 
treatment also decreased the amount of truncated protein N-linked oligosaccharides in 
these CDG fibroblasts. The increased cellular levels of Dol-P-Man in zaragozic acid-
treated cells also led to increased availability of the glycosylphosphatidylinositol-anchor 
as shown by the elevated cell surface expression of the CD59 protein. The present study 
shows that manipulation of the cellular Dol pool, as achieved by zaragozic acid addition, 
may represent a valuable approach aimed at improving N-linked glycosylation in CDG 
cells. 
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Introduction 
Congenital Disorders of Glycosylation (CDG)a are a group of inherited defects of protein 
glycosylation (Freeze, 2006). Mutations in genes encoding either proteins involved in 
biosynthesis of lipid-linked oligosaccharide (LLO) required for N-glycosylation (Jaeken 
and Matthijs, 2007) or proteins involved in glycan processing (De Praeter et al., 2000; 
Hansske et al., 2002) or transport of N-glycoproteins (Foulquier, 2008) form the 
molecular basis of CDG. The majority of CDG encompass disorders affecting the 
assembly of the LLO precursor dolichol-pyrophosphate (Dol-PP)-GlcNAc2Man9Glc3, 
which leads to under-occupancy of N-glycosylation sites (Haeuptle and Hennet, 2009). 
The stepwise biosynthesis of the LLO precursor begins at the cytosolic side of the 
endoplasmic reticulum (ER) membrane by transfer of GlcNAc-P to dolichol-P (Dol-P) 
and completes at the luminal side of the ER membrane. Dol-P does not only serve as 
carrier of maturing LLO, but also as lipid component of Dol-P-Man and Dol-P-Glc, both 
donor substrates for luminally acting mannosyl- and glucosyltransferases (Kornfeld and 
Kornfeld, 1985). 
The symptoms associated to CDG are principally of neurologic nature, such as 
psychomotor retardation, ataxia and hypotonia but also include hormonal alterations 
and coagulopathies (Leroy, 2006). The clinical severity of CDG mainly depends on the 
degree of N-glycosylation site under-occupancy (Hülsmeier et al., 2007), which itself 
depends on the available pool of complete LLO Dol-PP-GlcNAc2Man9Glc3. To date, only 
two forms of CDG can be successfully treated by oral carbohydrate supplementation. 
The glycosylation defects resulting from deficiency of Man-P isomerase (MPI) can be 
corrected by Man supplementation (Niehues et al., 1998; Westphal et al., 2001), whereas 
Fuc uptake has been shown to rescue the deficiency of GDP-Fuc transport (Marquardt et 
al., 1999). Considering the involvement of Dol throughout the LLO biosynthetic pathway, 
we made the hypothesis that increased cellular levels of Dol and Dol-P based substrates 
may increase the formation of Dol-PP-GlcNAc2Man9Glc3 in CDG. 
Dol biosynthesis follows the sterol pathway up to the formation of the C15-intermediate 
farnesyl-PP (Swiezewska and Danikiewicz, 2005) (Fig. 1A). Instead of squalene 
formation by head to head assembly of two farnesyl-PP molecules (Muscio et al., 1974), 
the consecutive condensation of isopentenyl-PP units leads to the diverging synthesis of 
polyprenyl-PP, a pre-stage of Dol-P. The enzyme squalene synthase catalyzes the first 
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reaction leading exclusively to the formation of sterol compounds, such as cholesterol 
and steroid hormones (Fig. 1A). Inhibition of squalene synthase, for example by 
zaragozic acid A (ZGA), leads to the stimulation of prior diverging pathways, and hence 
to increased formation of Dol and Dol-P (Keller, 1996). ZGA, also known as  
 
Figure 1: Statins acting on the sterol biosynthesis pathway. (A) The biosynthetic formation of sterols, 
such as cholesterol, starts from acetyl-CoA and leads via the C15-intermediate farnesyl-PP to its various 
endproducts. The involved enzymes are numbered as follows: (1) acetoacetyl-CoA thiolase, (2) HMG-CoA 
synthase, (3) HMG-CoA reductase, (4) mevalonate kinase, (5) phosphomevalonate kinase, (6) mevalonate-
PP decarboxylase, (7) isopentenyl-PP isomerase, (8) farnesyl-PP synthase, (9) squalene synthase, (10) 
squalene monooxygenase, (11) squalene epoxydase, (12) Dol-P-Man synthase, (13) protein 
farnesyltransferase, (14) geranylgeranyl-PP synthase, (15) protein geranylgeranyltransferase. At the 
point of farnesyl-PP, the pathway diverges to the formation of prenylated proteins, ubiquinone or Dol. The 
polyisoprene Dol-P is incorporated into Dol-P-Man, a key intermediate in protein glycosylation and GPI-
anchor formation. While pravastatin, lovastatin and rosuvastatin lower cellular cholesterol levels by 
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inhibiting the pathway at the stage of the HMG-CoA reductase, ZGA achieves this by inhibiting the 
squalene synthase. The chemical structure of ZGA is depicted in (B). 
squalestatin I, was discovered by screening metabolites of filamentous fungi for 
cholesterol lowering activity (Bergstrom et al., 1995). Detailed analysis disclosed that 
ZGA acts as a competitive inhibitor of the squalene synthase by mimicking the farnesyl-
PP substrate or the stable intermediate presqualene-PP with its bicyclic, highly acidic 
core (Fig. 1B). In contrast to statins acting on common steps of both Dol and cholesterol 
biosynthesis, such as the 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) 
reductase inhibitors pravastatin (Koga et al., 1990), lovastatin (Alberts et al., 1980) or 
rosuvastatin (McTaggart et al., 2001), ZGA does not negatively affect the diverging 
pathways generating Dol, ubiquinone or prenylated proteins (Fig. 1A). In the present 
study, we have investigated the ability of the squalene synthase inhibitor to increase Dol 
biosynthesis and thereby the output of N-glycosylation in CDG fibroblasts. 
 
Experimental Procedures 
Materials - ZGA was a gift from Merck & Co., Inc. (Rahway, NJ). The C80-polyprenyl-P 
standards were purchased from Larodan Fine Chemicals (Sweden), and broad range 
mammalian Dol-P standards were from Sigma-Aldrich (Switzerland). Acetonitrile 
(Scharlau, Spain), dichloromethane (Sigma-Aldrich) and water (Sigma-Aldrich) were of 
HPLC grade, other chemicals were of analytical grade. 
Cholesterol analysis – Human primary skin fibroblasts (4 x 107 cells) cultured in DMEM 
(Sigma-Aldrich) with 10% fetal calf serum (Bioconcept, Switzerland) at 37°C were 
treated for 72 h with either 100 μM ZGA or DMSO alone as negative control. Cells were 
harvested by trypsinization, washed in PBS and centrifuged at 1000 x g for 5 min. To the 
cell pellet 1 ml of 4 % (w/v) KOH in 90 % ethanol was added. After vortexing, the 
solution was incubated for 10 min in a ultrasonic bath and transferred to a glass tube. 
After addition of 80 µl of internal standard (0.1 mg/ml epicoprostanol (Sigma-Aldrich) 
in pyridine), the solution was saponified for 60 min at 60°C, mixed with 1 ml of water 
and extracted three times with 2 ml heptane. The pooled heptane extracts were dried 
under nitrogen and derivatized with 75 µl BSTFA (Machery-Nagel, Oensingen, 
Switerzland) in 75 µl pyridine at 60°C for 60 min. For GC/MS analysis, the derivative 
mixture was diluted 5-fold with heptane and 1 µl was injected (injector temperature: 
280°C; splitless injection). A Restek RTX-1MS (BGB Analytik AG, Böckten, Switzerland) 
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column (15 m, ID = 0.25 mm) was used for chromatographic separation of the sterols. 
The carrier gas was helium at a constant flow of 1.5 ml/min. After a dwell time of 3 min 
at 90°C, the oven temperature was raised to 200°C at 20°C/min, then to 260°C at 
1.5°C/min, and finally held at 260°C for 10 min. Mass spectrometry was performed on a 
Finnigan PolarisQ ion trap mass spectrometer. Mass spectra were acquired in the mass 
range of m/z = 50 - 550. 
Dol-P analysis – Fibroblasts (4 x 107 cells) were harvested and centrifuged at 1000 x g 
for 5 min. Cell pellets were dissolved in 12 ml of water/methanol (1:1). Prior to alkaline 
hydrolysis (Elmberger et al., 1989), 15 μg of C80-polyprenyl-P standards were added. 
The extracted Dol and Dol-P were purified on a C18 Sep Pak column (Waters, USA) and 
subsequently separated on a Silica Sep Pak column (Waters) (Haeuptle et al., 2010). The 
Dol-P were dimethylated using diazomethane generated in an Aldrich diazomethane 
generator system (Sigma-Aldrich) according to the manufacturer’s instructions. The 
resulting Dol-P-Me2 were selectively demethylated by overnight incubation in tert-
butylamine (Sigma-Aldrich) at 70°C (Yamada et al., 1986). Monomethylated Dol-P 
samples were dissolved in a saturated solution of 9-anthryldiazomethane (Sigma-
Aldrich) in diethylether and incubated for 6 h on ice in the dark. Anthracene labeled Dol-
P were separated from non-reacted labeling agent by organic extraction (Yamada et al., 
1986). The purified products were dissolved in acetonitrile/dichloromethane (3:2) and 
subjected to HPLC on an Inertsil ODS-3 column (5 μm, 4.6 x 250 mm; GL Sciences Inc., 
Japan) equipped with a precolumn. Isocratic elution in acetonitrile/dichloromethane 
(3:2) and 0.01% diethylamine (Sigma-Aldrich) was performed at a flow rate of 1 ml/min 
(Yamada et al., 1986). Fluorescent labeled Dol-P were detected by excitation at 365 nm 
and emission at 412 nm. Defined amounts of internal standard C80-polyprenyl-P were 
used for quantification. 
Determination of Dol-P-Man - Approximately 4 x 107 fibroblasts were grown for 72 h in 
DMEM containing low Glc (5 mM; Sigma-Aldrich), supplemented with 2% fetal calf 
serum and 100 μM ZGA or DMSO as negative control. Low Glc medium was utilized to 
achieve improved Man incorporation (Korner et al., 1998). Cellular Dol-P-Man was 
metabolically labeled, extracted and purified according to the protocol of Körner and co-
workers (Korner et al., 1998). Briefly, the fibroblasts were labeled by incubation in 
DMEM containing 0.5 mM Glc and 125 µCi [3H]-Man (Hartmann Analytic, Germany) for 
30 min. Dol-P-Man and short LLO were extracted once with chloroform/methanol (2:1) 
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and twice with chloroform/methanol (3:2). The combined organic phases were dried 
and washed. Thin-layer chromatography on Silica gel 60 plates was performed in 
chloroform/methanol/water (65:25:4). The plates were analyzed by radiography after 
signal enhancement with an EN3HANCE spray (PerkinElmer, USA) and the area 
containing Dol-P-Man were scraped and counted in a TRI–CARB 2900 TR liquid 
scintillation analyzer (Packard, USA). 
CD59 flow cytometry - Fibroblasts (2 x 105 cells) were harvested by trypsinization, 
washed once in PBS containing 2% fetal calf serum and incubated with a FITC 
conjugated mouse anti-human CD59 antibody (BD Pharmingen, USA) diluted 1:100 in 
PBS containing 2% fetal calf serum for 20 min on ice (Imbach et al., 2000). Fibroblasts 
were washed and analyzed on a BD FACSCanto II flow cytometer (BD Biosciences, USA) 
equipped with BD FACSDiva software (BD Biosciences). 
LLO and N-linked oligosaccharide (NLO) analysis - The LLO profiles of 1.5 x 107 
fibroblasts treated for 72 h with either 100 μM ZGA or DMSO were analyzed as 
described (Haeuptle et al., 2008). The cells were starved for 45 min in fetal calf serum- 
and Glc-free DMEM (Invitrogen) and metabolically labeled for 60 min by addition of 150 
μCi [3H]-Man. LLO were extracted from cell pellets and oligosaccharides were released 
by mild acid hydrolysis in 0.1 N HCl. Glycoproteins recovered from the LLO extraction 
were denatured and NLO were released by overnight incubation with PNGaseF 
endoglycosidase (New England BioLabs, USA) (Grubenmann et al., 2002). 
Oligosaccharides were purified by ion-exchange chromatography on AG1-X2 and 
AG50W-X8 resins (Bio-Rad, USA) and by hydrophobic chromatography on Supelclean 
ENVI-Carb 120/400 beads (Supelco, USA) and C18 Sep Pak columns and subjected to 
HPLC analysis. 
Statistics - Results were expressed as mean ± SEM. The one-way ANOVA test with 
Bonferroni’s multiple comparison post-test was applied to confirm differences between 
groups. Significance was accepted for p<0.05. 
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Results 
The toxicity of ZGA was first determined by incubating human primary skin fibroblasts 
for ten days with increasing concentrations from 10 to 500 µM. ZGA was tolerated by 
fibroblasts up to a concentration of 125 µM. Above that concentration, the rate of cell 
proliferation slowed down and cell morphology was altered (data not shown). The 
addition of 100 µM ZGA to healthy control and CDG fibroblasts led to a moderate 
decrease of cellular cholesterol levels by 15% and 30%, respectively (Fig. 2). 
 
Figure 2: Analysis of cholesterol in healthy control and DPM1-CDG fibroblasts. Steady-state cholesterol 
levels were determined in fibroblasts by GC/MS after organic extraction. Cholesterol levels relative to the 
protein amounts of the extracted mock treated cells are shown as white bars and cholesterol levels of ZGA 
treated fibroblasts are shown as gray bars. Data are represented by mean ± SEM of three independent 
experiments, * p<0.05.  
 
The effect of ZGA on glycosylation was determined by measuring cellular levels of Dol-P, 
Dol-P-Man, a glycosylphosphatidylinositol (GPI)-anchored model protein, LLO and NLO. 
The impact of ZGA on Dol-P levels was first addressed on healthy control fibroblasts. 
After labeling with the fluorochrome 9-anthryldiazomethane, Dol-P levels were 
quantitated after HPLC separation (Haeuptle et al., 2010). The resulting fluorescent 
HPLC profiles of untreated cells (Fig. 3A) and of cells treated with 100 μM ZGA for 72 h 
(Fig. 3B) were compared. The pattern of Dol-P species changed upon ZGA treatment, 
where the amount of longer C100- and C105-Dol-P increased in ZGA treated fibroblasts 
(Fig. 3C). 
To address the effect of ZGA on various parameters of LLO biosynthesis in CDG, we 
chose fibroblasts with a deficiency of Dol-P-Man synthase-1 (DPM1) (Imbach et al., 
2000), which present low Dol- 
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Figure 3: Analysis and quantification of Dol-P levels in mock and ZGA treated control fibroblasts. (A) 
Control cells were grown in the presence of DMSO. Cellular Dol-P were labeled with the fluorophore 9-
anthryldiazomethane and separated by HPLC. The enlarged section in the fluorescent profile highlights 
the separation of the particular Dol-P species. The elution times of mammalian Dol-P standards ranging 
from C90- to C105-Dol-P are indicated below the section. The internal C80-polyprenol-P standard utilized for 
quantification eluted at a retention time of 33.5 min. (B) The separation of Dol-P from ZGA treated control 
fibroblasts is presented in the enlarged section, and the respective Dol-P species were assigned like in (A). 
Quantification was accomplished by comparison with the internal standard hexadecaprenyl-P eluting at 
34.2 min. (C) The Dol-P levels from four independent HPLC runs were calculated and normalized to 107 
fibroblasts. White bar represent Dol-P originating from mock treated and gray bars Dol-P from ZGA 
treated cells. Data are represented by mean ± SEM of four independent experiments, * p<0.05. 
 
P-Man levels, an accumulation of the LLO Dol-PP-GlcNAc2Man5 and the corresponding 
GlcNAc2Man5 glycan structure on glycoproteins. Dol-P-Man production was measured 
after labeling cells with [3H]-Man. The [3H]-Dol-P-Man pool determined in DPM1-
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deficient fibroblasts reached 65% of the levels measured in healthy control cells (Fig. 4). 
When DPM1-deficient fibroblasts were treated with 100 µM ZGA for 72 h, the [3H]-Dol-
P-Man levels increased by reaching 120% of normal values. Similarly, when healthy 
control fibroblasts were incubated with 100 µM ZGA, the levels of [3H]-Dol-P-Man 
increased by 150% (Fig. 4).  
 
Figure 4: Determination of Dol-P-Man levels in mock and ZGA treated fibroblasts. Dol-P-Man was 
metabolically labeled in control and DPM1-CDG fibroblasts by incorporation of [3H]-Man and thereafter 
extracted. The purified lipids were separated by TLC and, on the basis of radiography, the regions 
corresponding to [3H]-Dol-P-Man were scraped and quantified by liquid scintillation. Normalization of 
Dol-P-Man levels relative to the protein amounts of the extracted mock treated cells are shown as white 
bars, while the normalized values of ZGA treated fibroblasts are shown as gray bars. Data are represented 
by mean ± SEM of four independent experiments, * p<0.05. 
 
DPM1 deficiency leads to reduced cell surface expression of GPI-anchored proteins, 
since Dol-P-Man is required for the assembly of the GPI anchor (Kinoshita et al., 1997). 
Accordingly, low levels of the GPI-anchored protein CD59 have been detected on the cell 
surface of DPM1-deficient fibroblasts (Imbach et al., 2000). The addition of ZGA led to 
increased expression of CD59 in healthy control (Fig. 5A) and DPM1-deficient fibroblasts 
(Fig. 5B), as monitored by flow cytometry. When DPM1-deficient fibroblasts were 
treated with 100 µM ZGA for 72 h, the cell surface levels of CD59 returned to the levels 
observed in untreated control fibroblasts (Fig. 5C). A time course experiment showed 
that the ZGA effect was maximal by 72 h of treatment, whereas longer periods did not 
increase CD59 expression further (Fig. 5C). The effect on CD59 expression was also 
maximal when applying ZGA at 100 μM, but changes were already visible with lower 
ZGA concentrations (Fig. 5D). 
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Figure 5: Cell surface expression of GPI-anchored CD59. (A) Control fibroblasts were stained with a FITC 
conjugated α-human CD59 antibody and analysed by flow cytometry. The fluorescent histogram shows 
unstained cells as gray solid line, mock treated cells as black solid line and ZGA treated cells as black 
dotted line. (B) CD59 expression on DPM1-CDG patient fibroblasts was monitored by flow cytometry. 
Experimental set up and specimen allocations were like for control cells in (A). (C) Control (white bars) 
and DPM1-CDG fibroblasts (gray bars) were incubated with 100 µM ZGA for varying time periods and the 
detected CD59 expressions were normalized to CD59 levels of untreated control fibroblasts. (D) Different 
concentrations of ZGA were administered to control (white bars) or DPM1-CDG (gray bars) patient 
fibroblasts for 72 hours. As in (C), the measured CD59 expressions were normalized to untreated control 
cells. Data are represented by mean ± SEM of three independent experiments. 
 
The biosynthesis of the LLO Dol-PP-GlcNAc2Man9Glc3 requires Dol as carrier of the 
growing oligosaccharide and as donor substrate for Dol-P-Man and Dol-P-Glc (Kornfeld 
and Kornfeld, 1985). In normal cells, only the complete LLO Dol-PP-GlcNAc2Man9Glc3 
can be detected (Fig. 6A). DPM1 deficiency  
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Figure 6: Analysis of ZGA on LLO profiles. Fibroblasts derived from a healthy control (A and B) or a 
DPM1-CDG patient (C and D) were treated for 72 hours either with 100 µM ZGA (B and D) or DMSO as 
control (A and C). Thereafter, the cells were metabolically labeled with [3H]-Man and the LLO were 
extracted and hydrolyzed by mild acid treatment. The released oligosaccharides were purified and 
separated by HPLC. The retention time of standard yeast oligosaccharides ranging from GlcNAc2Man1 (M1) 
to GlcNAc2Man9Glc3 (M9G3) are indicated at the top of the profiles. 
 
leads to the accumulation of the intermediate LLO Dol-PP-GlcNAc2Man5 (Fig. 6C) 
(Imbach et al., 2000; Kim et al., 2000). The amount of this incomplete LLO could be 
reduced by treatment of DPM1-deficient fibroblasts with 100 µM ZGA. The ratio of the 
abnormal Dol-PP-GlcNAc2Man5 peak to the mature Dol-PP-GlcNAc2Man9Glc3 peak was 
decreased from 54% to 17% under ZGA supplementation (Fig. 6D). By comparison, the 
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addition of 100 µM ZGA to control fibroblasts did not influence the quality of the LLO 
profile (Fig. 6B). 
After transfer from LLO to proteins, the NLO GlcNAc2Man9Glc3 is trimmed by 
glucosidases and mannosidases in the ER (Helenius and Aebi, 2004). The analysis of NLO 
after [3H]-Man labeling of control fibroblasts showed, as expected, GlcNAc2Man8, 
GlcNAc2Man9 and GlcNAc2Man9Glc1 as main oligosaccharide structures (Fig. 7A). In 
DPM1-deficient fibroblasts, several intermediary oligosaccharide structures ranging 
from GlcNAc2Man4 to GlcNAc2Man7 were found, whereas the normal oligosaccharides 
GlcNAc2Man8, GlcNAc2Man9 and GlcNAc2Man9Glc1 were under-represented (Fig. 7C). 
While ZGA treatment did not affect the NLO profile of control fibroblasts (Fig. 7B), it 
decreased the occurrence of abnormal N-linked glycans GlcNAc2Man4 to GlcNAc2Man7 
and increased the amounts of the normal NLO GlcNAc2Man8, GlcNAc2Man9 and 
GlcNAc2Man9Glc1 in DPM1-deficient fibroblasts (Fig. 7D). In these cells, the ratio of the 
pathologic GlcNAc2Man5 peak to the normal GlcNAc2Man9 peak was 422% and this ratio 
was decreased to 143% after addition of ZGA (Fig. 7D). This normalization of the NLO 
profile demonstrated the beneficial effect of ZGA treatment on N-glycosylation. 
Taken together, the present study showed that treatment of human CDG fibroblasts with 
the squalene synthase inhibitor ZGA stimulated Dol-P biosynthesis and thereby 
improved the level of N-glycosylation in conditions of limited substrate availability as 
encountered in DPM1-deficiency. In addition, the supplementation with ZGA resulted in 
the normalization of the expression of the GPI-anchored protein CD59 on DPM1-
deficient fibroblasts. 
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Figure 7: Protein N-glycosylation in ZGA treated fibroblasts. NLO from control (A and B) and DPM1-CDG 
patient fibroblasts (C and D) were separated by HPLC. The protein linked oligosaccharides were prepared 
by PNGaseF endoglycosidase release from metabolically labeled cells previously treated for 72 hours 
either with 100 µM ZGA (B and D) or DMSO as control (A and C). The retention times of GlcNAc2Man1 (M1) 
to GlcNAc2Man9Glc3 (M9G3) are marked at the top of the profiles. 
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Discussion 
Successful treatment of biosynthetic CDG is restricted so far to oral administration of 
Man to Man-P isomerase deficient (MPI-CDG) patients (Niehues et al., 1998; Westphal et 
al., 2001). The applied Man could be phosphorylated by hexokinase and allows 
functional bypassing of the defective isomerization of fructose-6-P to Man-6-P. In the 
group of Golgi-associated CDG, a deficiency of the Golgi GDP-Fuc transporter (SLC35C1-
CDG or leukocyte adhesion deficiency type II) (Lübke et al., 2001) could also be treated 
by simple supplementation of a monosaccharide. Oral Fuc administration induced the 
expression of fucosylated glycoproteins and within short terms, the clinical symptoms of 
a SLC35C1-CDG patient could be relieved (Marquardt et al., 1999). Moreover, a few 
elementary attempts have been conducted to treat phosphomannomutase-2 deficiency 
(PMM2-CDG), which forms by far the largest CDG subtype (Freeze, 2009). Mutations in 
the PMM2 gene lead to disrupted conversion of Man-6-P to Man-1-P, which acts as 
precursor of GDP-Man (Matthijs et al., 1997). However, Man-1-P is neither able to diffuse 
through biological membranes nor does a transport system exist. Thus, it needs 
chemical modification prior to direct administration to overcome this obstacle (Eklund 
et al., 2005; Hardre et al., 2007; Rutschow et al., 2002). Membrane permeable Man-1-P 
analogues were successful in restoring LLO biosynthesis in CDG patient cells, but such 
prodrugs were toxic, very unstable and had to be applied in high concentrations (Eklund 
et al., 2005). 
Shang and Lehrman discovered a metformin-stimulated Man specific transport activity 
in human fibroblasts (Shang and Lehrman, 2004). The resulting increased Man uptake 
was shown to be able to correct artificially induced defects in LLO biosynthesis and 
protein N-glycosylation in control and PMM2-CDG fibroblasts. However, the observation 
that the clinical phenotype of PMM2 deficiency could not be treated with dietary Man, 
which was actually effective in cellular models (Freeze, 2009), renders a therapeutic 
administration of metformin questionable. 
Our approach to increase Dol-P biosynthesis by inhibition of the squalene synthase 
offers a therapeutic perspective for inherited biosynthetic N-glycosylation defects 
featuring residual enzymatic activity. Conveniently, ZGA is well tolerated in animal 
experiments (Baxter et al., 1992; Bergstrom et al., 1993) compared to classical statins, 
which interfere with various isoprenoid-based biosynthesis pathways and are 
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associated to adverse effects (Silva et al., 2007). We could show that ZGA decreased 
cellular cholesterol levels, although only by 15-30%, indicating that membrane 
properties were likely unaltered due to this treatment. However, we cannot exclude an 
effect of the lowered cholesterol levels on the formation of glycolipid rafts, in which GPI-
anchored proteins partition. Accordingly, the increased expression of the GPI-anchored 
protein CD59 observed in ZGA-treated cells could be caused by increased Dol-P 
availability and altered raft distribution. By contrast, the positive effect of ZGA 
supplementation on Dol-P-Man levels and LLO patterns in DPM1-CDG fibroblasts are 
unlikely to be related to decreased cholesterol biosynthesis since the ER membrane is 
low in cholesterol levels (Liscum and Underwood, 1995). Nevertheless, the effects of 
ZGA on protein modifications, such as farnesylation and geranyl-geranylation, have not 
been investigated, so that we cannot dismiss an impact of such modifications on the N-
glycosylation pathway at this stage.    
The present study was based on DPM1-deficient fibroblasts because this form of CDG 
shows several measurable abnormalities along the biosynthesis of N-glycans and GPI-
anchored proteins. By contrast, PMM2-deficiency that represents the largest group of 
CDG cases (Haeuptle and Hennet, 2009), does not feature accumulating LLO 
intermediates. Consequently, incomplete oligosaccharides on glycoproteins are usually 
not encountered in PMM2-deficiency. However, the up-regulation of Dol-P dependent 
substrates by ZGA may be beneficial in normalizing the glycosylation disorders caused 
by deficiency of glycosyltransferases catalyzing the attachment of the last four Man and 
three Glc of the LLO precursor (Kornfeld and Kornfeld, 1985). 
Over the last decade, knockout mouse models for PMM2-, MPI- and DPAGT1-deficiency 
have been generated (DeRossi et al., 2006; Marek et al., 1999; Thiel et al., 2006). These 
works clearly showed that disruption of LLO biosynthesis lead to early embryonic 
lethality. In this context, it would be interesting to investigate whether the embryonic 
lethality of the homozygotes could be lagged to a later stage of development by treating 
pregnant heterozygous mice with ZGA according to Keller (Keller, 1996). In addition, the 
generation of viable CDG mouse models, for instance by introduction of selected point 
mutations, would allow detailed analysis of organ specific effects of ZGA in the context of 
inherited N-glycosylation deficiencies. This seems to be of particular interest, 
considering that Keller reported an enormous effect of ZGA on Dol and Dol-P pools in rat 
livers, but not in other organs such as brain, kidney, intestine or testis (Keller, 1996), 
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which was similarly observed in different brain cells (Crick et al., 1995). Subcutaneously 
administered ZGA might preferentially be taken up by mammalian livers via a specific 
hepatic transport mechanism, which was likewise proposed in other studies (Baxter et 
al., 1992; Bergstrom et al., 1993). Considering the frequent impairment of liver function 
in CDG patients (Leroy, 2006), the proposed hepatic transport system for ZGA would 
suggest that liver N-glycosylation may benefit from treatment with the compound. Along 
this line, it would be of interest to address the effect of ZGA supplementation in hepatic 
cell lines, since fibroblasts do not represent suitable cell models to study glycoprotein 
secretion. The generation of hepatic cell lines with inactivated glycosylation genes will 
represent an opportunity to study the regulation of N-glycosylation by ZGA and similar 
compounds. 
In conclusion, this study opens new perspectives in developing treatments of 
glycosylation deficiency by showing that manipulation of the dolichol biosynthesis 
pathway, as shown here by ZGA administration, represents a valid option. 
Footnotes 
a The abbreviations used are: CDG, Congenital Disorders of Glycosylation; Dol, 
dolichol; GPI, glycosylphosphatidylinositol; HMG-CoA, 3-hydroxy-3-methyl-
glutaryl Coenzyme A; LLO, lipid-linked oligosaccharides; NLO, N-linked 
oligosaccharides; ZGA, zaragozic acid A 
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Abstract 
Glycosylation is a complex form of protein modification occurring in the secretory 
pathway. The addition of N- and O-glycans affects intracellular processes like the folding 
and trafficking of most glycoproteins. To better understand the impact of glycosylation 
in protein folding and maturation, parameters like glycosylation site occupancy and 
oligosaccharide structure must be measured quantitatively. In the present chapter, we 
describe current methods enabling the determination of N-glycosylation by assessment 
of cellular dolichol-phosphate levels, dolichol-linked oligosaccharides and the occupancy 
of N-glycosylation sites. We also provide detailed methods for the analysis of O-
glycosylation, whose role in intracellular protein maturation is often overlooked. 
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1. Introduction 
Glycosylation is a widespread and complex form of modification, which adds signals and 
specific functions to glycoproteins. N-linked and O-linked glycosylation, which are the 
main forms of protein glycosylation, are structurally and functionally distinct. N-linked 
glycosylation is initiated in the endoplasmic reticulum (ER), where the oligosaccharide 
GlcNAc2Man9Glc3 is transferred co-translationally to selected asparagine residues of 
nascent glycoproteins. While still in the ER, oligosaccharides on glycoproteins are 
trimmed by glucosidase and mannosidase enzymes to GlcNAc2Man8. Later in the Golgi 
apparatus N-linked oligosaccharides undergo further trimming and elongation steps, 
which contribute to the structural diversity of N-linked glycosylation. In contrast to the 
co-translational beginning of N-glycosylation, O-linked glycosylation takes place on 
folded proteins and is initiated by the transfer of monosaccharides to serine and 
threonine residues. Some forms of O-glycosylation like O-fucosylation (Harris and 
Spellman, 1993) and O-mannosylation (Lommel and Strahl, 2009) begin in the ER, 
whereas mucin-type O-glycosylation (Tian and Ten Hagen, 2009) and the biosynthesis of 
glycosaminoglycan chains (Bishop et al., 2007) begin in the Golgi apparatus. 
N-glycosylation is important for the folding and trafficking of many glycoproteins 
(Helenius and Aebi, 2004). The inhibition of N-linked glycosylation, for example by 
tunicamycin, results in the accumulation of misfolded proteins in the ER, which is a 
strong stimulus of the UPR (Shamu et al., 1994). After trimming by glucosidase-I in the 
ER, N-linked oligosaccharides are bound by the chaperone proteins calnexin and 
calreticulin, which contribute to the folding of glycoproteins (Ellgaard et al., 1999). 
Furthermore, N-linked oligosaccharides are also recognized by the EDEM protein, which 
redirects misfolded proteins from the ER lumen to the cytosol for proteasome-mediated 
degradation. Another important signal carried by N-linked oligosaccharides is the 
mannose-6-phosphate epitope, which mediates the recognition and transfer of 
lysosomal proteins to their target organelle (Dahms et al., 1989). 
The most common form of O-glycosylation, i.e. mucin-type glycosylation, does not 
contribute to glycoprotein folding since it occurs in the Golgi apparatus. However, the 
trafficking and secretion of some glycoproteins requires proper mucin-type 
glycosylation, as demonstrated in the case of the hormone FGF23. Deficient initiation of 
mucin-type O-glycosylation alters the susceptibility of FGF23 to Golgi-localized 
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proteases, thereby inhibiting the maturation of active FGF23. Mucin-type glycosylation 
of FGF23 is initiated by the polypeptide N-acetylgalactosaminyltransferase-3 enzyme. 
Loss of this enzymatic activity leads to the disease tumoral calcinosis, which is also 
caused by FGF23 deficiency (Chefetz and Sprecher, 2009). 
Another example of glycosyltransferase-assisted trafficking is given by the OFUT1 O-
fucosyltransferase enzyme. This ER-localized glycosyltransferase adds fucose to the 
EGF-like repeats of proteins such as Notch and its ligands. Independent from its 
glycosyltransferase activity, OFUT1 also acts as a chaperone, which is essential for the 
transfer of Notch from the ER to the Golgi apparatus (Okajima et al., 2005). The 
contribution of O-linked glycosylation to glycoprotein folding and secretion is much less 
documented than in the case of N-linked glycosylation. This limited knowledge is 
certainly related to the technically difficult investigation of O-linked glycan structures. In 
fact, O-linked glycans are often densely clustered and these glycans cannot be released 
without significantly altering the polypeptide backbone. The O-glycanase enzyme from 
Streptococcus pneumoniae has a specificity limited to the O-linked disaccharide Ga -
3)GalNAc-O. By contrast, N-linked glycans can be conveniently cleaved at the first 
GlcNAc unit by the N-glycosidase F.  
 
2. N-glycosylation  
Proper N-linked glycosylation is required for folding and intracellular trafficking of 
glycoproteins. Deficiency in the biosynthesis of the precursor of N-glycans or in the 
processing of N-glycans in the ER can alter glycoprotein folding and induce UPR. The 
following methods can be applied to identify defects of oligosaccharide assembly and of 
N-glycosylation site occupancy in target cells.  
 
2.1. Dolichol phosphate analysis 
The oligosaccharide core consisting of GlcNAc2Man9Glc3 is first assembled on the 
polyisoprenoid carrier dolichol (Dol). Moreover, dolichol-phosphate (Dol-P) is also part 
of the glycosylation substrates Dol-P-Man and Dol-P-Glc, which account for the final 
extension of the oligosaccharide core in the ER. Considering the low levels of Dol-P 
based structures in cells, a sensitive Dol-P detection can be achieved by labeling with the 
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fluorescent compound 9-anthryldiazomethane. The procedure was originally described 
for tissue sample extraction (Elmberger et al., 1989) and we have adapted the method 
for cultured cells (Haeuptle et al., 2009). Detection of unlabeled Dol-P can also be 
achieved by negative ion electrospray mass spectrometry (ESI-MS), which, in 
combination to precursor ion fragmentation, provides detailed information on Dol-P 
composition and on the saturation state of the α-isoprene unit.  
 
2.1.1. Required materials 
Devices and materials 
- LaChrom D-7000 HPLC system (Merck), equipped with an Inertsil ODS-3 column 
(5 μm, 4.6 x 250 mm; GL Sciences Inc., Japan) with a precolumn and a LaChrom 
7485 fluorescence detector. 
 
- Nano-flow ESI-ion trap MS (Eksigent nano-LC, 3200 QTRAP-MS, AB/SCIEX) 
 
- C18 Sep-Pak and Silica Sep-Pak cartridges (Waters) 
 
Other reagents 
- 9-anthryldiazomethane (ADAM) (Sigma-Aldrich) 
 
- C80-polyprenol and C95-Dol-P standards (Larodan Fine Chemicals, Sweden) 
- Diazald (Sigma-Aldrich) 
 
- Carbitol (Sigma-Aldrich) 
 
2.1.2. Extraction and purification of Dol and Dol-P 
Adherent cells (about 3 x 108 cells) are washed in PBS after trypsinization and 
resuspended in 6 ml of water and then fixed by addition of 6 ml of methanol. The 
resulting suspension is transferred to a round bottom glass flask and 3 ml of 15 M 
potassium hydroxide are added for alkaline hydrolysis. An aliquot of the C80 polyprenyl-
phosphate (e.g. 15 µg) can be added as internal standard for subsequent quantification. 
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The round bottom flask is attached to a reflux cooler and incubated in a preheated oil 
bath at 100 °C for 1 h. This alkaline hydrolysis removes carbohydrates from the Dol-P 
carrier. The resulting lysate is transferred to a glass tube and methanol is added to a 
total volume of 15 ml. The suspension is mixed with 30 ml of 
methanol/dichloromethane (1:4, v:v) and incubated at 40 °C for 1 h. Discard the upper 
phase (methanol) and transfer the lower phase (dichloromethane) containing the 
extracted lipids to a glass tube suitable for centrifugation. Wash the organic phase with 
10 ml of dichloromethane/methanol/water (3:48:47, v:v:v). For phase separation, 
centrifuge at 6800 x g at room temperature for 10 min and discard the upper phase. 
Repeat this washing step four times, which ensures the removal of free sugars and salt 
from the sample. The organic phase is then dried under nitrogen gas. 
Dol and Dol-P are purified in two steps using C18- and silica-based chromatography 
resins. First, equilibrate the C18 Sep-Pak cartridge with 5 ml of methanol, followed by 5 
ml of chloroform/methanol (2:1, v:v) and 10 ml of methanol/water (98:2, v:v, 
supplemented with 20 mM phosphoric acid). The dried lipids from the extraction step 
are dissolved in 400 μl of chloroform/methanol (2:1, v:v) and diluted by adding 10 ml of 
methanol/water (98:2, v:v) supplemented with 20 mM phosphoric acid. Load the 
solution onto the C18 Sep-Pak cartridge and wash with 20 ml of methanol/water (98:2, 
v:v, supplemented with 20 mM phosphoric acid). To remove phosphoric acid from the 
cartridge, wash again with 10 ml of methanol/water (98:2, v:v) devoid of phosphoric 
acid. Dol and Dol-P can be eluted with 20 ml of chloroform/methanol (2:1, v:v) and 
collected in a new glass tube. The eluate should be neutralized by adding 100 μl of 25% 
ammonium hydroxide. 
The second purification step through Silica Sep-Pak cartridges allows the separation of 
Dol from Dol-P. First, equilibrate the cartridge with 10 ml of 
chloroform/methanol/water (10:10:3, v:v:v) and 40 ml of chloroform/methanol (2:1, 
v:v, in 0.5% ammoniumhydroxide). Place a new glass tube to collect the dolichol 
fraction, which will be in the flowthrough of the chromatography. Apply the neutralized 
eluate from the previous step onto the Silica Sep-Pak cartridge. Rinse the glass tube of 
the eluate with 10 ml chloroform/methanol (2:1, v:v, in 0.5% ammoniumhydroxide) and 
load it onto the Silica cartridge. Repeat the process with10 ml chloroform/methanol 
(2:1, v:v, in 0.5% ammonium hydroxide). Elute Dol-P into another glass tube by applying 
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30 ml chloroform/methanol/water (10:10:3, v:v:v) onto the Silica cartridge. Dry the Dol 
and Dol-P fractions under nitrogen gas at 50 °C. 
 
2.1.3. Anthryldiazomethane labeling of Dol-P 
Dol-P labeling is made in two steps. First, Dol-P is dimethylated and then selectively 
demethylated to produce mono methylated <mono-methylated, monomethylated?> Dol-
P (Dol-P-Me). The procedure yields an enhanced fluorescence signal when labeling Dol-
P-Me with 9-anthryl derivatives (Yamada et al., 1986). The second step is the 
derivatization of Dol-P-Me with 9-anthryldiazomethane (ADAM). We use the 
diazomethane generator system (Sigma-Aldrich) for the dimethylation of Dol-P1. It 
consists of two glass tubes: a small internal tube placed inside a larger outer tube. The 
dried Dol-P fraction is first dissolved in 1 ml of diethylether and transferred into the 
large outer glass tube of the diazomethane generator. The glass that contained the Dol-P 
fraction is washed twice with 1 ml of diethylether, which is added to the outer tube of 
the diazomethane generator. To produce diazomethane, add 0.367 g Diazald (explosive!) 
to the inner tube of the diazomethane generator system. Dissolve Diazald by addition of 
1 ml of Carbitol. Assemble the two parts of the diazomethane generator system and 
immerse it into an ice bath. Make sure that the generator system is sealed. Using a 
syringe, carefully add 1.5 ml of 37% potassium hydroxide dropwise to the inner tube of 
the diazomethane generator system. Add few drops first and wait until the reaction 
starts, as seen by formation of gaseous diazomethane in the Diazald solution. In this way, 
the content of the inner tube is prevented from spilling into the outer tube. Then, 
carefully add the rest of the potassium hydroxide. Gently mix the reactants and incubate 
the reaction for 1 hour in the ice bath. The diethylether phase containing Dol-P should 
turn yellow by then, indicating an excess of diazomethane. After disassembly of the 
diazomethane generator, leftover reactants can be neutralized by addition of 0.15 g of 
silicic acid to the inner tube.  
The outer tube should be sealed with parafilm and left for 2 h at room temperature. The 
Dol-P-Me2 solution is transferred to a glass extraction tube and dried under nitrogen 
gas. To selectively demethylate Dol-P-Me2, dissolve it in 4 ml of tert-butylamine and 
                                                        
1
 Diazomethane is very toxic in contact with eye, skin or by inhalation. Diazomethane may explode in contact 
with sharp edges and when heated beyond 100 °C. 
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incubate at 70 °C for 14 h. Make sure to seal the extraction tube completely to prevent 
the loss of tert-butylamine. Then, evaporate tert-butylamine under nitrogen gas and 
dissolve Dol-P-Me in 1.5 ml of 0.1 M hydrochloric acid adjusted to pH 3 with sodium 
hydroxide. Extract Dol-P-Me twice with 3 ml of diethylether and dry the combined 
extracts under nitrogen gas. Labeling is performed in 1 ml of diethylether saturated with 
ADAM. Prepare the ADAM solution in a separate glass tube by gradually adding the 
reddish ADAM powder to 0.7 ml of diethylether until saturation. Take 600 μl of the 
yellowish ADAM solution and add it to the dried Dol-P-Me fraction. Incubate the labeling 
reaction at 4 °C in the dark for 8h. After drying under nitrogen gas, dissolve the reaction 
products in 2.4 ml of n-hexane. Wash the hexane phase three times with 1.8 ml of 
acetonitrile. Discard each time the acetonitrile lower phase. Dry the n-hexane phase 
under nitrogen gas. The ADAM labeled Dol-P-Me fraction can be dissolved in 
acetonitrile/dichloromethane (3:2, v:v) for HPLC analysis. 
 
2.1.4. HPLC analysis of fluorescently labeled Dol-P 
ADAM-derivatized Dol-P are separated by HPLC using an Intertsil ODS-3 column and 
applying isocratic elution according to Yamada et al. (Yamada et al., 1986). The mobile 
phase consists of acetonitrile/dichloromethan (3:2, v:v) supplemented with 0.01% 
diethylamine. ADAM fluorescence is detected at 412 nm using an excitatory wavelength 
of 365 nm. 
 
2.1.5. Negative ion electrospray mass spectrometry of Dol-P 
Purified Dol-P can also be directly analyzed by ESI-MS (Haeuptle et al., 2009) without 
derivatization. The dried Dol-P sample is first dissolved in 90% acetonitrile, 10% n-
hexane, containing 0.01% diethylamine, and then vortexed and centrifuged to eliminate 
any particulate matter. The nano-flow system consists of an injector fitted with a 10 µl 
fused silica capillary loop, coupled in-line to a nano-flow pump and emitter tip of a nano-
electrospray ion source via 20 µm ID fused silica capillary tubing. An aliquot of the 
sample is loaded into the injector loop and switched in-line to the nano-flow system, 
introducing the sample directly into the ion source with the dissolution solvent at a flow 
rate of 400 nl/min. Using a 3200 AB/Sciex QTRAP MS, all mass spectra are acquired 
manually in the Enhanced MS scan mode (ion trapping mode), scanning from m/z 1000 
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to m/z 1700 at a scan rate of 1000 amu/sec and a step size of 0.06 amu. The curtain gas 
flow is maintained at 10 psi, collision gas pressure at 4 x 10e-5 torr (High), interface 
heater temperature at 150 °C, declustering potential at -200V, entrance potential at  -
10V, collision energy at -10V and the ion spray voltage is varied between -2400 and -
4500 V, depending on the condition of the emitter needle. Fragment ion spectra of 
selected Dol-P precursor masses are acquired in the Enhanced Product Ion mode (EPI 
mode, fragmentation in ion trapping mode) with the collision energy set to -100V and 
linear scanning starting at m/z 100. Extensive rinsing of the nano-flow system in 
between sample injections is necessary to avoid cross contamination. 
 
2.2. Dolichol-linked oligosaccharide analysis 
Defects of Dol-linked oligosaccharide (DLO) assembly decrease the availability of the 
mature Dol-PP-GlcNAc2Man9Glc3 core for glycosylation of acceptor Asn sites on nascent 
glycoproteins (Hülsmeier et al., 2007). Such a DLO shortage leads to the non-occupancy 
of N-glycosylation sites, which impacts on protein folding and trafficking (Helenius and 
Aebi, 2004). DLOs are conveniently analyzed either by metabolic labeling using [3H]-
mannose, or by derivatization with the fluorochrome 2-aminobenzamide (2AB). The 
extraction, hydrolysis, and purification procedure of DLOs is common to both methods. 
 
 
2.2.1. Required materials 
Chemicals 
In addition to the solvents mentioned in section 0, you need the reagents listed below. 
- 3H-labeled  D-mannose, 5 mCi (Hartmann Analytics, Germany) 
 
- 2-Propanol (Sigma-Aldrich) 
 
- Trizma base (Sigma-Aldrich) 
 
- 2-Aminobenzamide (Sigma-Aldrich) 
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- Sodium cyanoborohydride NaBH3CN, (Sigma-Aldrich) 
 
Devices and other materials 
- Dowex AG 1 x 4, Dowex AG 50 x 8 (Bio-Rad) 
 
- ENVI-C18 and ENVI-Carb resin (Supelco) 
 
- Ultrafree-MC centrifugal filter devices (Millipore, Cat. No.: UFC30LH25) 
 
- Supelcosil LC-NH2 column, 5 μm particle size, 250 x 4.6 mm (Supelco) 
 
- Scintillation flow monitor FLO-ONE A-525 (Packard) 
 
2.2.2. [3H]-labeling of DLOs 
Approximately 2 x 108 are washed three times with PBS to remove Glucose from the 
medium. Cells are then incubated in DMEM without serum and glucose at 37 °C for 45 
min. After this starving step, [3H]-mannose (125 μCi / 108 cells) is added to the cells, 
which are incubated further at 37 °C for 1 h.  
 
2.2.3. Extraction of DLOs 
The labeling medium is aspirated and cells are washed quickly with 13 ml of ice-cold 
PBS. Cells are then fixed by adding 11 ml of ice-cold methanol/0.1 M Tris-HCl (8:3, v:v) 
and collected by scraping when dealing with adherent cells. The cell suspension is 
transferred to a 50 ml conical tube and 12 ml of chloroform are added. After vigorous 
mixing using a vortex, the suspension is centrifuged at 6000 x g for 10 min. The upper 
methanol phase and the lower chloroform phases are discarded, while the interface 
precipitate is kept for further extraction of DLOs. To this end, add 3 ml of 
chloroform/methanol/water (10:10:3, v:v:v), vortex for 2 min and spin at 6000 x g for 
10 min. Transfer the supernatant to a glass extraction tube. Repeat the extraction three 
times using 2 ml of chloroform/methanol/water (10:10:3, v:v:v). Then dry the extracted 
DLOs under nitrogen gas. 
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2.2.4. Hydrolysis and purification of oligosaccharides 
Acid hydrolysis is used to release the oligosaccharide from the lipid carrier. For this, 
incubate the extracted DLOs in 2 ml of 0.1 M hydrochloric acid (in 50% 2-propanol) at 
50 °C for 1 h, then neutralize by adding 1 ml of 0.2 M NaOH. To purify oligosaccharides, 
prepare a disposable chromatography column with 1ml of Dowex AG 1x4 resin, followed 
by 0.6 ml of Dowex AG 50x8 resin. Equilibrate the column with 20 ml of 30% 2-propanol 
and apply the 3 ml hydrolyzate, then wash with 3 ml of 30% 2-propanol. Collect the 
flowthrough (6 ml total) into a new glass tube and evaporate under nitrogen gas. A 
second column system is used to further purify the DLOs. Prepare a column with 0.2 ml 
of ENVI-C18 resin and 1 ml of ENVI-Carb 120/400 resin. Place a C18 Sep-Pak cartridge on 
top of the prepared column. Wash the system with 5 ml of 100% methanol, 5 ml of 
100% acetonitrile and 5 ml of water/acetonitrile/0.1 M ammonium acetate. Finally, 
equilibrate with 9 ml of 2% acetonitrile/0.1 M ammonium acetate. Resuspend the dried 
oligosaccharide sample in 1 ml of acetonitrile/0.1 M ammonium acetate and apply it 
onto the column. Wash the sample vial with 1 ml of acetonitrile/0.1 M ammonium 
acetate, which is then loaded onto the column. Make sure that the lower ENVI resin 
column does not run dry during the loading process. Wash the column system with 9 ml 
of acetonitrile/0.1 M ammonium acetate. To elute DLOs, add 6 ml of water/acetonitrile 
(3:1, v:v) and collect the eluate in a new glass tube. The pure oligosaccharides are then 
dried under nitrogen gas. 
 
2.2.5. HPLC analysis of [3H]-labeled oligosaccharides 
A Supelco LC-NH2 normal phase column (including a LC-NH2 guard column) and a two 
solvent system are used for HPLC separation (Zufferey et al., 1995). Prepare 
acetonitrile/water (7:3, v:v) and acetonitrile/water (1:1) as mobile phases. Dissolve the 
purified oligosaccharides in 50-100 μl water for injection. The separation is carried out 
by running a gradient from acetonitrile/water (7:3, v:v) to acetonitrile/water (1:1) over 
75 min at a flow rate of 1 ml/min. The [3H]-labeled oligosaccharides are detected using a 
flow scintillation detector. When the level of [3H]-incorporation is too low for detection 
by flow scintillation, fractions of the HPLC run can be collected and measured separately 
in a scintillation counter (Müller et al., 2005). While more time consuming, the latter 
detection yields a superior signal to noise ratio. 
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2.2.6. 2-aminobenzamide labeling of DLOs 
The labeling of oligosaccharides with 2-aminobenzamide (2AB) is performed according 
to Bigge et al. (Bigge et al., 1995). For 2AB labeling, DLOs are extracted as described 
under section 2.2.3 and oligosaccharides are purified as outlined under section 2.2.4. 
Dried oligosaccharides are resuspended in 200 μl water/acetonitrile (3:1, v:v) and 
transferred to a 1.5 ml, screw cap Eppendorf tube, where they are dried again. The 2AB 
labeling reagent is prepared by dissolving 24 mg 2AB in 500 μl acetic acid/DMSO (3:7, 
v:v) and adding 31 mg sodium cyanoborohydride, thereby achieving a 0.35 M 2AB and 1 
M sodium cyanoborohydride solution. Add 20 μl of the labeling reagent to the dried 
oligosaccharides, mix by vortexing and incubate at 65 °C for 2 h. After cooling, add 380 
μl acetonitrile to the sample. Excess labeling reagent is removed using the paper disk 
clean up procedure (Müller et al., 2005).To this end, punch paper disks from a Whatman 
3MM paper using an office hole puncher. Place two paper disks in a centrifugal filter 
device and wash with 450 μl of water by spinning 30 s at 2000 x g. Wash the filter twice 
with 450 μl 95% acetonitrile and load the labeled samples. Let the sample pass through 
the paper disks without spinning the filter device. Wash six times with 450 μl 95% 
acetonitrile followed by a quick spin at 2000 x g. Elute the labeled oligosaccharides by 
applying three times 50 μl of water and spinning briefly at 2000 x g. 
 
2.2.7. HPLC analysis of 2AB-labeled oligosaccharides 
To separate 2AB-labeled oligosaccharides, we have adapted the procedure of Royle et al. 
(Royle et al., 2002) using a three buffer solvent system (Grubenmann et al., 2004). We 
use a GlykoSep-N column maintained at 30 °C. Solvent A consists of 80% acetonitrile 
with 10 mM formic acid (pH 4.4) and solvent B of 40% acetonitrile with 30 mM formic 
acid (pH 4.4). The 50 mM formic acid stock solution is adjusted to pH 4.4 with 
ammonium hydroxide. Solvent C is 0.5% formic acid (pH is not adjusted). The gradient is 
run from 100% solvent A to 100% solvent B over 160 min at a flow rate of 0.4 ml/min. A 
transition from 100% solvent B to 100% solvent C follows within 2 min at a flow rate of 
1 ml/min. 
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2.3. N-glycosylation Site Occupancy 
Most defects of N-glycosylation result in partial occupancy of N-glycosylation sites on 
proteins. The quantitative analysis of glycosylation site occupancy is not trivial because 
glycosylated glycosylation sites usually ionize less efficiently than native peptides and it 
is not feasible to synthesize adequate standard glycopeptides for quantification 
purposes. Due to the structural microheterogenity of glycopeptides the relatively low 
sensitivity in detection is further compromised. Therefore, we developed a strategy to 
simplify the analysis and quantification of glycosylation site occupancy by 
deglycosylating the N-linked glycopeptides with N-glycosidase F. As an example, we 
describe here the analysis of human serum transferrin, which carries two N-glycans at 
Asn413 and Asn611. We showed previously that Asn611 glycosylation is most sensitive to 
cellular stress imposed by congenital disorders of glycosylation or alcohol abuse 
(Hülsmeier et al., 2007). Serum transferrin is immune-
proteolytically digested and N-glycans are removed by digestion with N-glycosidase F, 
which converts the corresponding glycosylated Asn to Asp. N-glycosidase F digestion in 
buffer constituted with isotopic water (H218O) leading to the incorporation of 18O into 
the respective Asp, which allows to monitor for potential spontaneous deamination of 
unoccupied Asn prior to digestion with N-glycosidase F. The inclusion of isotopic labeled 
standard peptide enables sensitive and accurate quantitation of deglycosylated versus 
unoccupied glycosylation sites. The generated glycosylation sequon peptides are then 
analyzed by liquid chromatography multiple reaction monitoring mass spectrometry 
(LC-MRM-MS)2. We are using a nanoflow LC (Eksigent) coupled to a hybrid type QTRAP-
MS (ABSciex 3200 QTRAP-MS) equipped with a nano-electrospray ionization source. 
With this instrumentation the triple quadrupole mode MRM-MS can be combined 
sequentially with product ion scanning in ion trapping mode, or in a MRM signal induced 
product ion scanning mode. MRM has the advantage that selected fragment transitions 
are measured resulting in high specificity, sensitivity and reproducible signals for 
quantitation over a wide range of signal intensities. In our setup, the product ion 
scanning serves as an additional scanning mode to confirm the sequence of the peptide 
ion selected in the first quadrupole ion filter. 
 
                                                        
2
 MRM is also referred to as single reaction monitoring mass spectrometry (SRM MS) and can be considered 
synonymous to MRM. 
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2.3.1. Required devices and materials 
- Multiple Affinity Removal LC Column, 4.6 x 50 mm, with proprietary buffer 
system (MARS LC column “Human 6” or custom made “Human 3” for IgG, 
transferrin and antitrypsin, Agilent Technologies) 
 
- Iodoacetamide (Sigma Ultra grade) 
 
- Endoproteinase Asp-N (Roche Diagnostics GmbH) 
 
- Trypsin (Roche Diagnostics GmbH, proteomics grade) 
 
- N-Glycosidase F (Roche Diagnostics GmbH) 
 
- Aprotenin (Roche Diagnostics GmbH) 
 
- 20 mM ammonium bicarbonate, dissolved in 97 atom % H218O, Cambridge 
Isotope Laboratories Inc.) 
 
- Custom synthesized, isotope labeled peptides (≥90% purity, HeavyPeptide Basic 
kit, Thermo Electron Corp.) 
 
- Multiple reaction monitoring- (MRM-) capable nano-LC-MS system 
 
- C18 PepMap 100 trap column (300-μm inner diameter × 5 mm, Dionex) 
 
- C18 PepMap100 column (75-μm inner diameter × 15 cm, 3 µm, 100 Å, Dionex) 
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2.3.2. Purification of transferrin 
A sample aliquot containing transferrin corresponding to 5 µl human serum is diluted 
ten times with Agilent buffer A3 and loaded onto the MARS column according to the 
manufacturer instructions.  Transferrin will be eluted from the column in one step with 
100% Agilent buffer B. The chromatography can be monitored by UV absorption at 280 
nm and the transferrin containing peak fraction is collected. The eluate is desalted and 
concentrated by TCA precipitation. The samples are cooled on ice and adjusted to 12% 
TCA by adding 0.136 volumes of 100% TCA. The samples are kept on ice for 30 min or 
ideally at -20°C overnight and centrifuged for 30 min at 14000 x g. The supernatants are 
discarded and the pellet is washed twice with 300 µl ice-cold (-20 °C) acetone. 
Centrifuge for 15 min at 4 °C and 14000 x g each time after adding the acetone. 
 
2.3.3. Proteolytic digestion and deglycosylation of glycopeptides 
The TCA precipitated protein pellet is dissolved by sonication in 250 µl of 0.57 M Tris-
HCl, pH 8.5, 50 mM DTT (1M DTT diluted 20-fold with 0.6 M Tris-HCl, pH 8.5). Proteins 
are incubated for 5 min at 80°C, cooled to room temperature and cysteine residues are 
alkylated by adding 63 µl of 1M iodoacetamide (5-fold excess over DTT, freshly 
prepared). The samples are incubated at room temperature in the dark for 40 min and 
subsequently desalted by TCA precipitation (see section 2.3.2). The alkylated proteins 
are re-dissolved in 50 µl of 20 mM ammonium bicarbonate, containing 10% acetonitrile. 
Then 0.5 µg of endoproteinase Asp-
incubated at 37°C for 16 h. Proteolysis is minimized by heating the sample for 5 min at 
80°C, adding 0.5 µmol EDTA and 100 µg aprotinin. Then 8 pmol of each standard peptide 
is added and the sample is lyophilized overnight. The sample is re-dissolved in 50 µl of 
20 mM ammonium bicarbonate in 95 atom % H218O, 1.5 units of N-Glycosidase F 
(dissolved in 95 atom % H218O) is added and the sample is digested at 37°C for 8 h. The 
duration of the N-Glycosidase F digestion was empirically optimized and it is 
recommended to keep these conditions to avoid sample degradation or incomplete N-
Glycosidase F digestion. The reaction is stopped by heat inactivation at 80 °C for 5 min. 
                                                        
3
 Buffers A and B are supplied by Agilent together with the MARS column and their composition is proprietary. 
Therefore, we name these buffers “Agilent buffer A” and “Agilent buffer B”, respectively. 
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One tenth of the sample is adjusted to 20 µl of 0.1% formic acid in 2% acetonitrile and 
filtered through a 0.22 µm centrifugal filter device. 
 
2.3.4. Liquid chromatography multiple reaction monitoring mass spectrometry 
The sample is loaded on the trap column and the column is washed with 60 μl of 0.1% 
formic acid, 2% acetonitrile. After washing, the trap column is switched in line to the 
PepMap column and a binary gradient at 250 nl/min is applied with Buffer A 0.1% 
formic acid, and buffer B 80% ACN containing 0.1% formic acid. Buffer B is  held at 14% 
for 3 min, increased to 54% over 102 min and to 100% over 8 min, held at 100% for 12 
min, and decreased to 14% over 12 min, and the column is re-equilibrated at 14% buffer 
B for 16 min. The Asn413 peptides elute between 8 and 14 minutes and the Asn611 
peptides elute between 22 and 34 minutes retention time. The transferrin peptides 
containing N-glycosylation sites can be detected by multiple reaction monitoring mass 
spectrometry using the parameters listed under table 1. 
 
2.3.5. Calculation of the N-glycosylation site occupancies 
The average counts per second (cps) for each MRM transition are calculated by 
integrating the counts over the time of peak elution with the instrument acquisition 
software. The molar relative response factor (MRRF) for each peptide sequence is 
calculated by dividing the cps of the target peptide to the cps of the corresponding 
standard peptide.  
     
                 
                   
 
The percentage of site occupancies is calculated as follows: 
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3. O-glycosylation 
Mucin-type glycosylation is initiated in the Golgi apparatus and is therefore not directly 
involved in the UPR. However, mucin-type O-glycosylation is involved in the 
intracellular processing of glycoproteins and contributes to their stability at the cell 
surface.  
 
3.1. Release of O-glycans by the β-elimination reaction 
O-glycans linked to the hydroxyamino acids Ser or Thr can be released by mild alkali 
treatment. This mild alkali treatment induces the β-elimination reaction, releasing O-
linked carbohydrates from the β-carbon of Ser or Thr and leads to the formation of 2-
aminopropenoic acid or 2-amino-2-butenocic acid, respectively (Figure 1). A decrease of 
Ser or Thr after mild alkali treatment can be monitored by amino acid analysis, 
providing further information about the presence of O-glycosylation and the 
hydroxyamino acid involved in the O-glycosyl linkage (Hülsmeier et al., 2010; Hülsmeier 
et al., 2002). The released O-glycans are unstable under alkaline conditions and undergo 
stepwise degradation reactions termed “peeling reaction”. A second β-elimination 
reaction occurs at the reducing end GalNAc residue, resulting in the formation of a 
furanosyl compound, the Morgan Elson chromogen (Figure 1). The “peeling reaction” 
can be minimized by including sodium borohydride (NaBH4) to the reaction mixture, 
thereby reducing the aldehydic group of GalNAc to the corresponding primary alcohol 
N-acetylgalactosaminitol (GalNAc-ol). GalNAc-ol is stable under alkaline conditions. 
Further GalNAc can be isotopically labeled by using either sodium borodeuterite 
(NaBD4) or sodium borotritiate as reducing agents. A 2:8(mol:mol) mixture of NaBH4 
and NaBD4 can be used, which introduces a “fingerprint” isotope distribution into the O-
glycans, facilitating the identification of O-glycans in MALDI-MS and alleviating the 
assignments of fragmentation ion spectra by marking the reducing end C1 carbohydroxy 
group (Hülsmeier et al., 2002). 
 
3.1.1. Required devices and materials 
- Sodium borohydride, sodium borodeuterite (Sigma) 
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- Sodium hydroxide, purest available grade (Sigma) 
 
- Clean glass rod and glass tube 
 
- Methyl iodide (ReagentPlus, 99.5%, Sigma-Aldrich) 
 
- sodium thiosulphate (Sigma) 
 
- 2,5-dihydroxybenzoic acid  (Fluka) 
 
3.1.2. Reductive β-elimination 
The glycoprotein sample (1 mg or less) is lyophilized in a 1.5 ml screw cap 
polypropylene vial and dissolved in 200 µl freshly prepared 0.1 M sodium hydroxide, 
containing 0.2 M NaBH4 and 0.8 M NaBD4 (prepared by mixing 1M NaBH4 and 1M NaBD4 
solutions 2:8 by volume). The sample is incubated at 37°C for 24 h. Then further 100 µl 
of 0.1 M sodium hydroxide, containing 0.2 M NaBH4 and 0.8 M NaBD4 are added and 
incubation continues for further 48 h at 37°C. The reaction is stopped by carefully 
adding acetic acid until gas development ceases. The sample will be acidified to 
approximately pH 4. 
 
3.1.3. Purification of the β-eliminated O-glycans 
A C18 Sep-Pak cartridge is conditioned with 5 ml methanol, 5 ml propanol and 
equilibrated with 2 times 5 ml 1% acetic acid. A 0.6 ml Dowex AG50W-X12 column is 
conditioned with 3 times 5 ml 4 M HCl and washed with water until the flow through 
becomes neutral. The Sep-Pak cartridge is mounted on top of the Dowex column and 
both columns are equilibrated with 3 times 5 ml of 1% acetic acid. The β-elimination 
products are passed through the combined columns and the columns are washed twice 
with 2 ml of 1% acetic acid. The flow through is collected into a glass vial and dried 
under vacuum evaporation. Residual boric acid is removed by co-evaporation twice with 
250 µl 1% acetic acid in methanol and twice with 250 µl methanol. Residual acetic acid 
is removed by two evaporations with 50 µl of toluene. 
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3.1.4. Permethylation 
The permethylation derivatization is carried out according to the NaOH method 
(Ciucanu and Kerel, 1984). The purified O-glycans are dried from 100 µl of 10 mM 
triethylamine to improve the solubility of negatively charged glycans as triethylamine 
salts in dimethyl sulfoxide (DMSO). Then, 50 µl DMSO is added and the reaction vial is 
agitated for 20 min. A 120 mg/ml slurry of NaOH in DMSO is prepared by crushing NaOH 
pellets with a glass rod in a glass tube. The NaOH will not dissolve completely and 
precipitate. Mixing of the slurry is required prior application to the derivatization 
reaction. A 50 µl aliquot of the NaOH/DMSO slurry is added to the reaction vial 
containing the O-glycans and the vial is shaken for additional 20 min. Then, 10 µl of 
methyl iodide are added twice, and the vial is agitated for 10 min after each addition, 
followed by a final addition of 20 µl of methyl iodide and agitation of the vial for further 
20 minutes. Permethylated glycans are extracted by adding 250 µl of chloroform and 
500 µl of 1 M sodium thiosulphate. The vial is agitated thoroughly and the liquid phases 
are separated by centrifugation. The aqueous phase is discarded and the chloroform 
phase, containing the permethylated O-glycans is washed 10 times with 1 ml of water. 
The chloroform phase is vacuum dried and the permethylated O-glycans are re-
dissolved in 50 % acetonitrile for application to MALDI-mass spectrometry (MADLI-MS). 
 
3.1.5. MALDI-MS 
The MALDI matrix is prepared by dissolving 10 mg 2,5-dihydroxybenzoic acid (DHB) in 
1 ml of 50 % acetonitrile, containing 1 mM sodium chloride (Hülsmeier et al., 2010). 
Aliquots of the permethylated O-glycans are mixed on the MALDI plate with DHB matrix 
1:1 (v:v) and allowed to dry at room temperature. The dried spots are re-crystallized by 
applying less than 0.1 µl of ethanol. A 10 µl pipette tip is dipped into ethanol and some 
solvent will be taken up by capillary force. Ethanol outside the tip is evaporated by 
waving the tip in the air for a few seconds. Then the tip is placed over the dried DHB 
spot, that the ethanol solvent just touches the MALDI plate surface. The DHB crystals 
will dissolve quickly and are left to air dry. As a result an even layer of DHB crystals will 
be formed, permitting sensitive detection of the analytes. The re-crystallization can be 
repeated, if necessary. Additional DHB matrix can be added, if difficult samples are to be 
analyzed. MALDI mass spectra are recorded in positive ion mode and glycans are mainly 
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detected as their sodium ion adducts, due the presence of 1 mM sodium chloride in the 
DHB matrix. 
 
3.2. Release of O-glycans by hydrazinolysis 
Releasing O-glycans by hydrazinolysis has the advantage, that the glycans are liberated 
with a free reducing end saccharide. This allows subsequent labeling with fluorophores 
like 2AB or anthranilic acid, facilitating high resolution chromatographic separation 
combined with unparalleled sensitive fluorescence detection (see section 2.2.6-2.2.7, 
Figure 2). It is important for this reaction to occur under anhydrous conditions and that 
the sample is free of salt, metal ions, detergent, dyes and stains. The reaction mechanism 
during hydrazinolysis has not been elucidated so far. However, an initial formation of a 
hydrazone derivative with concomitant release of water seems to be likely. After re-N-
acetylation of the released glycans, acetohydrazone derivatives are formed and O-
glycans in unreduced form can be recovered after passage through cation exchange 
resin and the addition of Copper-(II)-acetate in mild acid (Patel et al., 1993). 
 
3.2.1. Required devices and materials 
- Water and methanol rinsed, oven dried 250 µl glass syringe 
- Glass reaction vials 
 
- Lyophilizer 
 
- Pure anhydrous hydrazine (Ludger Ltd, UK) 
 
- Ice cold, saturated sodium bicarbonate solution 
 
- Acetic acid anhydride (Sigma) 
 
- Dowex AG50 [+H-form] resin (Bio-Rad) 
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- Copper-(II)-acetate (Sigma) 
 
- Supelclean™ ENVI-18 resin (Sigma) 
 
3.2.2. Hydrazinolysis 
The glycoprotein sample is dialyzed against 0.1% TFA and transferred to a clean glass 
reaction vial. The sample is lyophilized extensively for one to three days, depending on 
the amount of protein (up to 5 mg protein). Then, anhydrous hydrazine is added 
immediately using a glass syringe, pre-rinsed with hydrazine. Hydrazine is added in 
excess to the sample to give a less than 5 mg protein per ml hydrazine solution. The 
reaction vessel is capped securely and mixed gently to bring the majority of sample into 
solution. The sample is transferred in a heating block at 60 °C and incubated for 5 h. The 
sample is cooled to room temperature and vacuum dried or lyophilized. Residual 
hydrazine can be removed from the sample by three times re-drying from 100 µl 
methanol and finally evaporation from 50 µl toluene. The vial is placed on ice and 100 µl 
of ice-cold saturated sodium-bicarbonate solution is added, followed by the addition of 
twice 10 µl acetic acid anhydride4. The sample is mixed and incubated at room 
temperature for 10 min. Then, a second aliquot of acetic acid anhydride is added and the 
incubation proceeds for further 20 min. The sample is passed through a 3 ml Dowex 
AG50 [+H-form] column, followed by 4 ml of water. The eluate is collected, dried and re-
dissolved in 2 ml of 1 mM Copper-(II)-acetate in 1 mM acetic acid. The sample is 
incubated at room temperature for 1 h and the O-glycans are purified by passage 
through a column of 2 ml ENVI-18 resin over 1 ml Dowex AG50 [+H-form] resin, eluted 
with water. The O-glycans are now ready for 2AB-derivatisation and HPLC analysis (see 
sections 2.2.6 and 2.2.7). 2AB-labeled  glycan can also be subjected to permethylation for 
analysis by MALDI-MS. In our hands, permethylation of 2AB-glycans leads to significant 
higher signal intensities in MALDI-MS compared to permethylation of alkaline 
borohydride reduced glycans. 
 
                                                        
4
 From our experience, re-N-acetylation with sodium bicarbonate can lead to partial O-acetylation reactions. O-
acetylation might are not evident in HPLC analyses, but can be detected in MALDI-MS. Here it can serve as an 
indicator for the presence of saccharide in precursor ion scanning experiments. Saccharides would be detected in 
MALDI with a characteristic satellite peak increment of 42 Da. 
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Table 1: Peptides used for transferrin glycosylation sites Asn413 and Asn611. Amino acids 
containing the isotope label are marked bold: F, +10 Da; L, +7 Da; A, +4 Da. Due to a 
misscleavage at Lys414 two sets of peptides are required. Two Asn413 sequon variants are 
generated at approximately equal abundance in the reaction mixture. The fragmentation 
conditions for each peptide were optimized empirically for maximum signal intensities. 
Dwell time, time per transition; DP, declustering potential; EP, entrance potential; CEP, 
collision cell entrance potential; CE, collision energy; CXP, collision cell exit potential. 
Designation Sequence m/z value Q3 ion 
Standard peptide Target peptide 
Asn413-NK CGLVPVLAENYNK 749.4  742.4 y9 
Asn413-NKS CGLVPVLAENYNKS 792.9 785.9 y10 
Asn413-DK CGLVPVLAENYDK 755.9 744.9 y9 
Asn413-DKS CGLVPVLAENYDKS 799.4 788.4 y10 
Asn611-NVT QQQHLFGSNVT 640.3 633.3 b5-NH3 
Asn611-DVT QQQHLFGSDVT 645.3 635.3 b9 
 
Designation Dwell time DP EP CEP CE CXP 
 (ms) (V) (V) (V) (V) (V) 
Asn413-NK 100 40 9.0 40 41 45 
Asn413-NKS 100 41 9.5 43 44 48 
Asn413-DK 100 41 9.0 40 41 45 
Asn413-DKS 100 41 9.5 43 44 48 
Asn611-
NVT 
150 40 9.0 35 37 43 
Asn611-DVT 150 40 9.0 35 37 44 
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Abstract 
In the majority of congenital disorders of glycosylation, the assembly of the glycan 
precursor GlcNAc2Man9Glc3 on the polyprenol carrier dolichyl-pyrophosphate is 
compromised. Because N-linked glycosylation is essential to life, most types of 
congenital disorders of glycosylation represent partial losses of enzymatic activity. 
Consequently, increased availability of substrates along the glycosylation pathway can 
be beneficial to increase product formation by the compromised enzymes. Recently, we 
showed that increased dolichol availability and improved N-linked glycosylation can be 
achieved by inhibition of squalene biosynthesis. This review summarizes the current 
knowledge on the biosynthesis of dolichol-linked glycans with respect to deficiencies in 
N-linked glycosylation. Additionally, perspectives on therapeutic treatments targeting 
dolichol and dolichol-linked glycan biosynthesis are examined. 
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Dolichol biosynthesis and its role in N-linked glycosylation 
N-linked glycosylation occurs in all domains of life and the same basic molecular 
principles underlie this post-translational modification (Larkin and Imperiali, 2011; 
Schwarz and Aebi, 2011). Briefly, an oligosaccharide precursor is assembled on a lipid 
carrier before the oligosaccharide is transferred to a target protein. In eukaryotes, N-
linked protein glycosylation requires the assembly of the oligosaccharide precursor at 
both the outer and inner leaflet of the ER membrane (Veneselli et al., 1998). The 
precursor is assembled on Dol-PP starting at the cytoplasmic side. The intermediate Dol-
PP-GlcNAc2Man5 is then flipped to the luminal side of the ER where the assembly 
proceeds to Dol-PP-GlcNAc2Man9Glc3. Note worthily, Dol serves as lipid carrier in 
eukaryotes and archaea whereas another isoprenoid alcohol, bactoprenol, is used in 
bacteria. Apart from its role as carrier of the oligosaccharide GlcNAc2Man9Glc3, Dol is 
used to form the activated monosaccharides Dol-P-Man and Dol-P-Glc, which are 
substrates for glycosyltransferases involved in N-glycosylation, O-mannosylation, C-
mannosylation and GPI-anchor biosynthesis. 
Dol biosynthesis begins at the mevalonate pathway (Fig. 1) (Armstrong et al., 1993; 
Raucy et al., 1991), which produces essential isoprenoids. Isoprenoids are divided into 
two classes: sterol isoprenoids, such as cholesterol and steroid hormones, and non-
sterol isoprenoids, encompassing polyprenols, ubiquinone, and Dol. Starting from 
acetyl-CoA via acetoacetyl-CoA, 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) is first 
produced. The reduction from HMG-CoA to mevalonate is catalyzed by the rate-limiting 
HMG-CoA reductase (HMGCR) enzyme. Mevalonate is then phosphorylated to 
mevalonate-P by mevalonate kinase (MVK). A second phosphorylation step and 
subsequent decarboxylation leads to isopentenyl-5-pyrophosphate (IPP), which 
represents an important building block for isoprenoids. IPP is an activated isoprene unit 
of five carbon atoms and is used to form farnesyl-pyrophosphate. At this point, the 
pathway diverges to feed on the one hand the biosynthesis of cholesterol and on the 
other hand the biosynthesis of non-sterol isoprenoids. To obtain Dol, dehydrodolichyl 
diphosphate synthase (DHDDS) catalyzes the stepwise head-to-tail cis addition of IPP to 
farnesyl-pyrophosphate, thus giving rise to polyprenyl-pyrophosphates of 15 to 19 
isoprene units. These polyprenyl-pyrophosphates are then dephosphorylated by pyro- 
or monophosphatases. The resulting polyprenols are reduced at the α1 position to 
become Dol of different lengths. Dol is then phosphorylated by Dol kinase (DOLK). Dol-P 
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can then be utilized as the carrier for the oligosaccharide GlcNAc2Man9Glc3 or as a 
carrier for Man and Glc. Dol-P-Man is produced by the Dol-P-Man synthase (DPM1-3) 
that transfers Man from GDP-Man to Dol-P while Dol-P-Glc is produced by the 
glucosyltransferase ALG5 that transfers Glc from UDP-Glc to Dol-P. 
Importantly, Dol levels at the cytoplasmic leaflet of the ER are not only maintained by de 
novo synthesis but also depend on recycling of discharged Dol-PP and Dol-P. Once the 
oligosaccharide precursor is transferred to a target protein, Dol-PP is released and 
dephosphorylated to Dol-P by the luminal phosphatase DOLPP1 (Rush et al., 2002). Dol-
P is then flipped across the membrane to the cytoplasmic leaflet by a yet unknown 
mechanism (Rush et al., 2008). Recycling of Dol-P and Dol-PP contributes significantly to 
the Dol pool available glycosylation in the ER. Consequently, a defect of the DOLPP1 
orthologue in yeast leads to impaired N-linked glycosylation (van Berkel et al., 1999). 
 
Deficiency of dolichol biosynthesis – a new family of CDG 
Several forms of congenital disorders of glycosylation (CDG) caused by Dol biosynthesis 
defects have been characterized recently. The long sought polyprenol reductase has 
been identified though the description of SRD5A3-CDG (Cantagrel and Lefeber, 2011) 
and DHDDS deficiency was discovered in a subgroup of retinitis pigmentosa patients 
(Ghosh et al., 1993a). Moreover, the clinical picture of Dol kinase deficiency was 
extended through the description of new cases presenting with dilated cardiomyopathy 
(Jung et al., 1999). 
Proximal to Dol, a defect along the mevalonate pathways has also been linked to 
diseases. Mutations in the mevalonate kinase gene (MVK) (Fig. 1) cause of two different 
forms: mevalonic aciduria (MVA) (Barone et al., 1999) and hyperimmunoglobulinemia D 
syndrome (HIDS) (Valnot et al., 1999). In MVA, MVK activity is reduced to 0-4% of the 
normal values. Patients die in early childhood. Typcial symptoms (Table 1) are 
psychomotor retardation, failure to thrive, progressive cerebellar ataxia, dysmorphic 
features, progressive visual impairment and frequent febrile attacks (Raucy et al., 1991; 
Sturla et al., 2003; Valliere-Douglass et al., 2009). Psychomotor retardation, failure to 
thrive, dysmorphic features, and visual impairment are also frequently found in CDG, 
thus suggesting possible glycosylation problems in MVA. HIDS is a milder form of the 
disease correlating with the residual MVK activity of 5-15% of normal values. In HIDS, 
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febrile attacks and skin rashes start in early childhood and can be triggered by diverse 
events, such as vaccinations or minor infections. The febrile disposition is believed to be 
linked to insufficient levels of anti-inflammatory isoprenylated proteins. Low 
geranylgeranyl-PP in HIDS leads to caspase-1 activation and IL-1β secretion (Parfait et 
al., 1999; van der Knaap et al., 1999). Other symptoms found in HIDS (Table 1) are 
mental retardation, ataxia, ocular symptoms and epilepsy (Kim et al., 2008). Diagnosing 
HIDS involves the detection of increased mevalonic acid in urine and increased serum 
immunoglobulin D and A. Apart from febrile attacks, the clinical features of MVA and 
HIDS are reminiscent of CDG. Indeed, metabolic labelling experiments with 
[14C]galactose in MVK deficient fibroblasts revealed lower secretion of the radio-labelled 
macromolecules indicating impaired glycosylation, which is possibly due to decreased 
formation of Dol and Dol-P (Gebauer et al., 2008). However, systematic analysis of 
glycosylation in HIDS has not been performed yet. 
Recently, DHDDS deficiency (Fig. 1) has been linked to inherited retinitis pigmentosa 
(Ghosh et al., 1993a), a disorder causing retinal degeneration with an estimated 
incidence of 1 in 3,000-4,500. The single mutation identified was autosomal-recessive 
and present in a very small subgroup of retinitis pigmentosa patients (Haldar et al., 
1993). Interestingly, DHDDS patients did not show typical CDG symptoms despite the 
central role of DHDDS in Dol production (Table 1). This fact suggests that DHDDS 
mutations associated with retinitis pigmentosa only partially impair polyprenol-PP 
formation and that only few photoreceptor-specific proteins may be sensitive to a 
reduced polyprenol-PP pool. Note worthily, inhibition of N-linked glycosylation by 
tunicamycin also leads to retinal degeneration in Xenopus (Jenisch et al., 1999; Wimmer-
Greinecker et al., 1999). Retinitis pimentosa is also associated with MVK deficiency and 
with cases of phosphomannomutase 2 deficiency in PMM2-CDG (Grunewald, 2009). 
The third disorder of Dol biosynthesis is a recently described type of CDG, in which the 
SRD5A3 gene (Fig. 1) is affected (Fu and van Halbeek, 1992; Hart et al., 1988). SRD5A3 
encodes the steroid 5α reductase type 3 protein, which reduces the α-isoprene in 
polyprenol to form Dol. Symptoms of SRD5A3-CDG are typical for glycosylation 
disorders and encompass ocular malformations, cerebellar vermis hypoplasia, skin 
lesions, psychomotor retardation, and facial dysmorphism (Table 1). Strikingly, these 
multisystemic manifestations strongly differ from those found in DHDDS-CDG despite 
the proximity of the two enzymes in the Dol pathway.  SRD5A3-CDG features loss of 
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whole N-glycan chains on proteins. Different mutations of the SRD5A3 gene lead to 
truncated forms resulting in loss of function. Residual levels of Dol in SRD5A3 deficient 
cells suggest an alternative pathway for Dol biosynthesis.   
 
 
Figure 1: Dolichol and cholesterol biosynthesis pathway. Two acetyl building blocks 
are required for HMG-CoA formation. HMG-CoA reductase (HMGCR) catalyzes the rate 
limiting step, the formation of mevalonate. Mevalonate kinase (MVK) phosphorylates 
mevalonate in a CTP-dependent manner. Sequential action of dehydrodolichyl 
diphosphate synthase (DHDDS), pyro- or monophophatases, 5α steroid reductase type 
3 (SRD5A3), and dolichol kinase (DOLK) produce Dol-P. Dol-P-Man synthase (DPM1-3) 
transfers a mannose to Dol-P. Squalene synthase (FDFT1) produces squalene from 
farnesyl-PP and subsequent action of squalene epoxidase (SQLE), and 2,3-
oxidosqualene cyclase (OSC) leads to lanosterol. Dotted arrows indicate simplifications 
of the biosynthetic pathway and * point out known congenital defects in dolichol 
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biosynthesis of the respective enzymes. 
Dol kinase deficiency, characterizing DOLK-CDG, impairs the phosphorylation of Dol to 
Dol-P (Fig. 1). DOLK-CDG presents with severe phenotypes including hypotonia, skin 
disorders, and the loss of hair (Schindler et al., 1987). Moreover, cardiomyopathy, 
seizures, hypoglycemia, microcephaly, and visual impairment can occur as well (Table 
1). Due to the severity of the symptoms, most DOLK-CDG patients have died in early 
childhood. Reduced DOLK activity and the resulted low availability of Dol-P impair the 
assembly Dol-PP-GlcNAc2Man9Glc3 and hence N-linked glycosylation. Recently, 11 
children with dilated cardiomyopathy (DCM), a disease possibly linked to sudden 
cardiac death and heart failure, were found to have a novel mutation in DOLK (Jung et 
al., 1999). Besides DCM, only few of the patients exhibit additional symptoms like 
ichtyosis, failure to thrive, and mild neurological involvement. Biochemical analysis of 
Dol-P dependent glycosylation pathways of the DCM heart tissue indicated reduced O-
mannosylation of α-dystroglycan (Ijland et al., 1999). Remarkably, abnormal N-
glycosylation of serum transferrin was equally pronounced in both forms of DOLK-CDG. 
The phenotypes of DCM strongly contrast with the originally described features of 
DOLK-CDG, thus suggesting a possible tissue-specific regulation of Dol-P dependent 
glycosylation. 
Human Dol-P-Man synthase (DPM1-3, Fig. 1) consists of 3 subunits. DPM1 is the 
catalytic subunit and DPM2/3 are regulatory and membrane anchoring proteins 
residing in the ER membrane (Maeda and Kinoshita, 2008). So far, two forms of Dol-P-
Man synthase deficiency have been described featuring mutations in the DPM1 and 
DPM3 genes. DPM1-CDG is characterized by recurrent seizures, hypotonia, 
developmental delay, dysmorphic features, microcephaly, visual impairment, and in 
some cases ataxia and coagulopathy (Table 1) (Chen et al., 2005; Kreishman et al., 1972; 
Palamarczyk and Janczura, 1977; Tao et al., 2006). Lower Dol-P-Man levels lead to 
impaired Dol-PP-GlcNAc2Man9Glc3 assembly, abnormal N-linked protein glycosylation, 
and decreased formation of GPI anchored proteins. DPM3-CDG appears to be a milder 
form of Dol-P-Man synthase deficiency, for which only one patient has been found so far 
(Zaia, 2013). The symptoms included mild myopathy, a dilated cardiomyopathy, 
moderate muscular dystrophy, and a single stroke-like episode. The adult patient is able 
to live a practically normal life. N-glycosylation of serum transferrin is only slightly 
abnormal. In DPM1-CDG and DPM3-CDG, the severity seems to reflect the molecular 
Publications – Regulation of dolichol-linked glycosylation 
   
93 
 
functions of the affected subunits. So, a deficient catalytic subunit, DPM1, leads to a 
much more severe phenotype than a deficient tethering subunit, DPM3.  
 
Table 1: Disorders of dolichol biosynthesis and their respective symptoms. 
Symptoms are distinguished between ** for typical/dominant symptoms and * for 
sporadic symptoms or symptoms of moderate severity. 
 
a) Classical DOLK-CDG, b) DOLK defect in dilated cardiomyopathy.  
 
 
MVA HIDS 
DHDDS-
CDG 
SRD5A3-
CDG 
DOLK-
CDGa) 
DOLK-
CDGb) 
DPM1-
CDG 
DPM3-
CDG 
Cardiomyopathy 
   
* ** ** 
 
* 
Cerebellar ataxia / 
malformation 
** ** 
 
** 
  
** 
 
Coagulopathy 
   
** 
  
** 
 
Dysmorphic features ** 
  
** ** 
   
Failure to thrive ** 
       
Febrile attacks ** ** 
      
Hypoglycemia 
    
** 
   
Hypotonia 
    
** 
 
** 
 
Microcephaly ** * 
  
** 
 
** 
 
Muscular dystrophy 
      
** * 
Myopathy 
      
** * 
Ocular malfunctions ** 
 
** ** ** 
 
** 
 
Psychomotor retardation ** ** 
 
** ** * ** 
 
Seizures ** * 
  
** 
 
** 
 
Skin disorders ** ** 
 
* ** * 
  
In general, the clinical severity of Dol-related diseases does not correlate with the 
relative position of the deficient enzymes along the biosynthesis pathway. Defects of Dol 
biosynthesis are generally expected to be severe since not only the assembly of Dol-PP-
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GlcNAc2Man9Glc3 is impaired, but also GPI anchor formation and O-mannosylation are 
affected. This notion is confirmed in SRD5A3-CDG that present with severe 
multisystemic phenotypes. However, the discovery of DHDDS-CDG with a very specific 
phenotype and lack of the typical CDG symptoms suggests a complex regulation of Dol-
dependent glycosylation. Future efforts addressing the regulation of Dol biosynthesis 
should provide a better understanding of the question and open the way to novel 
therapeutic perspectives. 
 
Therapeutics targeting dolichol 
To date, only two forms of CDG are treatable. MPI-CDG can be successfully treated with 
oral mannose supplementation (Liu et al., 2006; Tissot et al., 2007). In GFTP-CDG, GDP-
fucose transporter deficiency can be compensated with nutritional fucose 
supplementation (Marquardt et al., 1999). The hypomorphic nature of most CDG 
mutations allows for a compensatory approach, for instance by providing more Dol to 
overcome the compromised assembly of Dol-PP-GlcNAc2Man9Glc3. Along this line, 
inhibition of squalene synthase (FDFT1, Fig. 1) was shown to improve N-linked protein 
glycosylation and GPI-anchored protein expression in DPM1-CDG fibroblasts (Haeuptle 
et al., 2011). We tested potential drugs such as clofibrate for its ability to increase GPI 
anchor availability in DPM1-CDG fibroblasts. Clofibrate is a fibrate known to decrease 
cholesterol levels by targeting lipid metabolism via activation of peroxisome 
proliferator-activated receptors, especially PPARα (Abourbih et al., 2009; Forman et al., 
1997). Indeed, GPI anchor availability was improved upon clofibrate treatment as 
observed by an increased surface expression of the GPI anchored protein CD59 
(unpublished data). In another approach to increase the Dol pool, we attempted to 
increase DHDDS activity by treatment of DPM1-CDG fibroblasts with the AMP cyclase 
activator forskolin (Losfeld et al., 2012). DHDDS activity was previously shown to 
increase with higher cyclic AMP levels (Konrad and Merz, 1994; Konrad and Merz, 
1996). Treatment of DPM1-CDG fibroblasts with forskolin led to higher levels of surface 
CD59 as well. 
New therapeutic possibilities arise for CDG with the advance of non-statin cholesterol 
lowering drugs, which target the late pathway of cholesterol biosynthesis. Presently, 
statins are the prevalent medication to lower cholesterol and decrease cardiovascular 
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disease (Hoenger et al., 1993). Statins are inhibitors of the HMG-CoA reductase (Fig. 1), 
the rate limiting enzyme at the beginning of the mevalonate pathway. The effect of 
statins on Dol levels has not been investigated systematically. Hela cells treated with 
pravastatin showed a decrease in Dol-P by 65% (Kornfeld et al., 1985). However, rats 
treated with lovastatin did not show a change of total Dol-P levels but increase of Dol-P 
in the liver (Low et al., 1992). The potential of different statins to upregulate Dol could 
be investigated in a screen. For instance, CDG fibroblasts treated with an array of statins 
could be screened for changes of Dol levels. 
Inhibition of the first committed enzyme of cholesterol biosynthesis, squalene synthase 
(FDFT1, Fig. 1), has proven effective in lowering cholesterol production (Dhar et al., 
1993). Prominent among these inhibitors are zaragozic acids, which were identified in a 
screen of fungal compounds for cholesterol lowering activity (Bergstrom et al., 1995). 
Changes in Dol-P patterns were observed in human fibroblasts treated with zaragozic 
acid A. Also, DPM1-CDG fibroblasts showed improved N-linked glycosylation upon 
treatment with zaragozic acid A (Takahashi et al., 1993). Moreover, the expression of the 
GPI-anchored CD59 protein could be normalized in DPM1-CDG fibroblasts after 
treatment. Since zaragozic acid is well tolerated in animals (Baxter et al., 1992; 
Bergstrom et al., 1993), this class of FDFT1 inhibitors might be considered for clinical 
testing in some cases of CDG. 
Squalene epoxidase (SQLE) catalyzes the next committed step of cholesterol 
biosynthesis after FDFT1 (Fig. 1). Therefore, inhibition of SQLE is considered to 
specifically lower cholesterol. Inhibition of SQLE by the compound NB-598 ((E)N-ethyl-
N-(6,6-dimethyl-2-hepten-4-ynyl)-3-[(3,3'-bith iophen-5-yl)methoxy]benzene-
methanamine) successfully reduced cholesterol levels (Ghosh et al., 1993c; Hope et al., 
1993), although no changes in Dol levels were detected in treated HepG2 cells (Ghosh et 
al., 1993b). In spite of this early finding, newly developed SQLE inhibitors should be 
considered as promising candidates for an upregulation of Dol in CDG cells. Moreover, 
green tea has been attributed a cholesterol lowering effect, which is linked to SQLE 
inhibition (Abe et al., 2000). In a recent study, oral supplementation with the main green 
tea catechin epigallocatechin gallate was shown to lower LDL-cholesterol (Wu et al., 
2012). The effects of epigallocatechin gallate on Dol have not been tested yet. Catechins 
might represent another option to upregulate Dol in CDG cells by inhibition of SQLE. 
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Oxidosqualene cyclase (OSC) inhibitors interfere with the conversion of 2,3-
oxidosqualene to lanosterol (Fig. 1). Due to adverse effects, the development of such 
inhibitors has been stopped (Hope et al., 1993). Unless novel OSC inhibitors without 
adverse effects are discovered, the potential of such drugs to increase the Dol pool is not 
worth further investigation. 
In conclusion, inhibitors of late cholesterol biosynthesis have a potential increasing 
effect on Dol levels and should be accordingly tested in CDG cells. Much effort is invested 
in the development of cholesterol lowering drugs in the context of cardiovascular 
diseases. Therefore, potential CDG therapies could profit from the discovery of novel 
cholesterol lowering drugs in the future.  
 
Outlook 
The recent identification of tissue-restricted symptoms in DHDDS-CDG and of a novel 
pathology associated to DOLK deficiency suggests a pronounced tissue specificity of Dol-
related biology. Accordingly, additional diseases are likely to be associated with local 
alterations of Dol biosynthesis in the near future.  The study of these tissue-restricted 
diseases represents valuable models to better understand the regulation of Dol 
biosynthesis and its impact on various types of glycosylation. Novel therapeutic 
approaches may be deduced from such insights. The treatment of CDG is still very 
limited and merits further attention. We believe that interference of cholesterol 
production and thus upregulation of Dol biosynthesis represents a valuable approach to 
improve glycosylation in CDG. High-throughput screenings of existing cholesterol 
lowering drugs that upregulate Dol are relatively straightforward and could open novel 
therapeutic opportunities. 
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Abstract 
Background 
Deficiency in N-linked protein glycosylation is a long-known characteristic of alcoholic 
liver disease and congenital disorders of glycosylation. Previous investigations of 
ethanol-induced glycosylation deficiency demonstrated perturbations in the early steps 
of substrate synthesis and in the final steps of capping N-linked glycans in the Golgi. The 
significance of the biosynthesis of N-glycan precursors in the endoplasmic reticulum, 
however, has not yet been addressed in alcoholic liver disease.  
Methods 
Ethanol-metabolizing hepatoma cells were treated with increasing concentrations of 
ethanol. Transcript analysis of genes involved in the biosynthesis of N-glycans, activity 
assays of related enzymes, quantification of dolichol-phosphates, and analysis of 
dolichol-linked oligosaccharides were performed. 
Results 
Upon treatment of cells with ethanol, we found a decrease in the final N-glycan 
precursor Dol-PP-GlcNAc2Man9Glc3 and in C95- and C100-dolichol-phosphate levels. 
Transcript analysis of genes involved in N-glycosylation showed a 17% decrease in 
expression levels of DPM1, a subunit of the dolichol-phosphate-mannose synthase, and a 
8% increase in RPN2, a subunit of the oligosaccharyl transferase.  
Conclusions 
Ethanol treatment decreases the biosynthesis of dolichol-phosphate. Consequently, the 
formation of N-glycan precursors is affected, resulting in an aberrant precursor 
assembly. Messenger RNA levels of genes involved in N-glycan biosynthesis are not 
affected by ethanol treatment, indicating that the assembly of N-glycan precursors is not 
regulated at the transcriptional level. 
General Significance 
This study confirms that ethanol impairs N-linked glycosylation by affecting dolichol 
biosynthesis leading to impaired dolichol-linked oligosaccharide assembly. Together our 
data help to explain the underglycosylation phenotype observed in alcoholic liver 
disease and congenital disorders of glycosylation. 
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Highlights 
- Dolichol-phosphate levels are reduced after ethanol treatment 
- Assembly of the N-glycan precursor is impaired after ethanol treatment 
- Transcript levels of genes involved in N-glycosylation are slightly affected after treatment 
 
Keywords 
N-linked glycosylation, alcoholic liver disease, dolichol, dolichol-linked oligosaccharides 
 
Abbreviations 
ALD, alcoholic liver disease; CDG, congenital disorder of glycosylation; CDT, 
carbohydrate-deficient transferrin; Dol-P, dolichol-phosphate; Dol-PP, dolichol-
pyrophosphate; DPM1-3, dolichol-phosphate-mannose synthase subunits 1-3; RPN2, 
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1. Introduction 
Alcoholic liver disease (ALD) displays a broad spectrum of symptoms reflecting the 
diverse functions of the liver. Among the most prominent characteristics of ALD are fatty 
liver, hepatitis, and liver fibrosis. Hepatocytes are responsible for detoxification in the 
liver and thus for alcohol metabolism. Major metabolic changes in hepatocytes occur due 
to the constant need for ethanol oxidation. Ethanol conversion to acetate leads to a shift 
in the NAD/NADH ratio impairing glycolysis and lipolysis and initiating fatty acid 
synthesis. The inversion of glycolytic flux eventually results in alcoholic fatty liver 
(Purohit et al., 2009). Oxidative stress is evoked by reactive oxygen species from ethanol 
breakdown in hepatocytes and toll-like receptor 4 activation by LPS leaking from the gut 
into the blood stream (Wang et al., 2012; Zhu et al., 2012). This oxidative stress 
contributes to liver inflammation and can lead to liver fibrosis and eventually cirrhosis. 
Another clinical feature in ALD receiving less attention is alcohol-induced deficiency in 
N-linked protein glycosylation although it has been used as a marker for alcohol abuse 
(Stibler, 1991).  
ALD and congenital disorders of glycosylation (CDG) share some symptoms. Typically, 
CDG display systemic deficiencies like psychomotor retardation with variable 
neuromuscular involvement and additional features like hormonal abnormalities and 
coagulopathies (Leroy, 2006). Importantly, fatty liver, hepatitis, and liver fibrosis are 
also found in CDG indicating a possible role of glycosylation in ALD pathology. Indeed, 
CDG was linked to a fibrotic response in fibroblasts involving the insulin-like growth 
factor-binding protein 5 (Lecca et al., 2011). As in CDG, blood serum proteins originating 
from the liver are not glycosylated properly in ALD. For instance, the distribution of 
carbohydrate-deficient transferrin (CDT) glycoforms found in ALD and CDG are similar 
(Bean and Peter, 1993; de Jong et al., 1992; Petren et al., 1987; Vigo and Adair, 1982). 
The two glycosylation sites of transferrin are normally occupied with carbohydrates 
adding up to four branches carrying terminal sialic acids. Besides tetrasialo-transferrin, 
disialo-transferrin is the most prevalent glycoform of transferrin in blood serum. In ALD 
and CDG, asialo- and disialo-transferrin become more apparent and tetrasialo-
transferrin levels are reduced (Hülsmeier et al., 2007). In CDG, such a CDT pattern 
indicates a deficiency in the assembly of the N-linked glycan precursor in the ER 
(Filipovic and Menzel, 1981). 
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So far, glycosylation deficiency in ALD has been assessed at the levels of Golgi 
glycosylation and dolichol metabolism. However, N-linked glycosylation starts in the ER 
and requires the synthesis of an oligosaccharide precursor on dolichol-phosphate (Dol-
P). On the outer leaflet of the ER, one phospho-GlcNAc, one GlcNAc, and five Man are 
sequentially transferred to Dol-P before flipping the resulting Dol-PP-GlcNAc2-Man5 into 
the ER lumen. After the addition of four Man and three Glc residues, the complete N-
glycan precursor, Dol-PP-GlcNAc2-Man9-Glc3 is transferred en bloc to target proteins. 
Microsomes isolated from rat livers of chronically ethanol-fed animals showed a 
decrease in total dolichol by 36% (Cottalasso et al., 1998; Cottalasso et al., 1996). Acute 
treatment with ethanol of rats resulted in a reduction of total dolichol in liver 
microsomes by up to 52%. In a cell culture model, HepG2 cells treated with 50-100 mM 
ethanol showed decreased transcription of the 2,6-sialyltransferase(Garige et al., 2006; 
Garige et al., 2005; Rao and Lakshman, 1997; Rao and Lakshman, 1999). This enzyme is 
responsible for terminal sialylation of sugar chains of transferrin in the Golgi apparatus. 
The same effect was observed in the liver from chronically ethanol-fed rats. Additionally, 
the 2,6-sialyltransferase mRNA is destabilized by a 3’-untranslated region-specific 
binding protein. Notably, besides downregulation of 2,6-sialyltransferase other effects 
could cause CDT. Several intermediates along the biosynthesis of the N-glycan precursor 
might be affected, potentially leading to an altered distribution of glycoforms. In one 
study the site occupancy of serum protein glycosylation in an alcohol abusing subject 
was reported to be reduced to levels observed in patients with mild forms of CDG 
(Hülsmeier et al., 2007). Another study reported the loss of one or both N-glycans as the 
cause for CDT in patients with severe alcohol abuse (Peter et al., 1998). 
To understand the mechanisms underlying alcohol-induced glycosylation deficiency, we 
investigated the effects of ethanol exposure on the early steps of N-linked protein 
glycosylation in two cell models. Cultured hepatocytes usually lose the expression of 
drug metabolizing enzymes (Carter and Wands, 1988; Gapp et al., 2012; Luo et al., 2006; 
Utesch et al., 1992; Van Kaick et al., 1983). Therefore, we used two cell lines expressing 
ethanol metabolizing enzymes in our study. First, the HepaRG cell line derived from a 
human hepatocellular carcinoma with an inducible cytochrome p450 system which 
renders the cell line suitable as a model for metabolism of xenobiotics in the human liver 
(Crick and Carroll, 1987; Eggens et al., 1990; Eggens and Elmberger, 1990; Keller, 1986; 
Stoll et al., 1988; Yokoyama et al., 1989). Ethanol degradation via cytochrome p450 2E1 
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(CYP2E1) is a major pathway of ethanol metabolism and can be induced by DMSO 
treatment in HepaRG cells (Koop and Tierney, 1990; Lieber, 1999; Ohnishi and Lieber, 
1977). The second cell line, VA-13,  is derived from HepG2 cells, which expresses murine 
alcohol dehydrogenase 1 (ADH) (Clemens et al., 2002). Ethanol degradation via alcohol 
dehydrogenase is the second major pathway of ethanol metabolism in the liver. We 
tested the effect of ethanol metabolism in hepatocytes on the N-linked glycosylation 
pathway in the ER and found that N-linked glycosylation is affected at several stages 
along the biosynthetic pathway. 
 
2. Materials and Methods 
2.1 Cell lines and experimental conditions 
HepaRG cells were kindly provided by Dr. N. Zitzmann (Department of Biochemistry, 
University of Oxford, UK). HepaRG cells were seeded at a density of 2.6 x 104 cells/cm2 
and cultured in Williams’ Medium E (Sigma-Aldrich) supplemented with 10% FBS, 5 
g/ml insulin, 2 mM L-glutamine, and 50 M hydrocortisone hemisuccinate for two 
weeks. To induce maximal induction of the P450 enzymes, HepaRG cells were cultured 
for two additional weeks in the same medium added with 2% DMSO (Sigma) (Gripon et 
al., 2002). On day 24 after seeding, ethanol was added to the medium and culture flasks 
were sealed with Parafilm to prevent evaporation of ethanol. HepaRG cells were 
harvested and analyzed after 28 days in culture. VA-13 cells were a kind gift from Dr. 
D.L. Clemens (Department of Internal Medicine, University of Nebraska Medical Center, 
USA). VA-13 cells are HepG2 cells stably transfected with an expression plasmid 
carrying the murine alcohol dehydrogenase gene, Adh-1 (Clemens et al., 2002). VA-13 
cells were seeded at a density of 1.7 x 104 cells/cm2 and ethanol treatment was started 6 
h after seeding. VA-13 cells were harvested and analyzed 4 days after treatment start. 
 
2.2 Isoelectric focusing gel electrophoresis and immunoblotting 
Supernatant from cultured hepatoma cells was saturated with 0.4 mM ferric citrate in 
presence of 20 mM sodium hydrogen carbonate for 30 min. Samples were analyzed 
using pre-cast Novex pH 3-7 IEF gels (Invitrogen). Gels were run at 7 mA (500 V 
maximum voltage) for 4 h on ice. Proteins were transferred to a nitrocellulose 
membrane by Western blotting. Transferrin isoforms were visualized using polyclonal 
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rabbit anti-human transferrin primary antibody (DakoCytomation, Denmark) and 
peroxidase-coupled goat anti-rabbit secondary antibody (Vector Laboratories, USA). 
 
2.3 Alcohol dehydrogenase activity assay 
Alcohol dehydrogenase (ADH) activity was measured in cell lysates as previously 
described (Clemens et al., 1995). Activity was determined in an assay using ethanol and 
NAD as substrates. ADH activity was indirectly determined from the conversion of NAD 
by measuring NADH photometrically at 340 nm.  
 
2.4 Cytochrome P450 2E1 activity assay 
Cytochrome p450 2E1 activity was determined as described previously (Wu and 
Cederbaum, 2008). Microsomal fractions were prepared and assayed for CYP2E1 
activity using p-nitrophenol and NADPH as substrates. 
 
2.5 Quantitative PCR for transcript analysis 
Transcript analysis of the glycosylation pathway were quantified with an adapted 
method for  quantitative PCR in mice (Nairn et al., 2010).  Mann-Whitney statistical 
analysis was done using the InStat software (GraphPad). Significance was accepted for p 
< 0.05. 
 
2.6 Dolichol-phosphate-mannose synthase activity assay 
Cells were grown on 300 cm2 plates and collected by trypsinization. Prior to cell lysis, 
cells were washed twice in ice-cold PBS. The cells were lysed in 25 mM Tris-HCl, 150 
mM KCl, 1% Triton X-100, and cell debris was removed by centrifugation. Protein 
concentration was determined by BCA (Pierce). Dolichol-phosphate-mannose (Dol-P-
Man) synthase activity was assayed using 30 ml of cell lysate in 100 ml of reaction 
buffer, with the addition of 40 mg/ml Dol-P (Sigma-Aldrich Co.) and 17 mM GDP-[14C] 
mannose (Amersham Pharmacia Biotech). The reaction buffer contained 50 mM HEPES 
(pH 7.4), 25 mM KCl, 5 mM MgCl2, 5 mM MnCl2, and 0.2% Triton X-100. Reaction 
mixtures were incubated for 5 min at 37°C. Dol-P-Man was isolated by organic 
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extraction with chloroform/methanol (2:1 vol/vol), and radioactivity was determined in 
a beta counter (Beckman Coulter Inc., Fullerton, California, USA) (McLachlan and Krag, 
1994). Statistical significance was determined by paired student t-test. Significance was 
accepted for p < 0.05. 
 
2.7 Fluorescent labeling and analysis of dolichol-phosphate 
Extraction, labeling, and analysis of Dol-P were adapted from previous studies 
(Elmberger et al., 1989; Haeuptle et al., 2010). Briefly, approximately 3 x 108 cells were 
collected by trypsinization, counted, and washed once in PBS. For quantification, 10 g 
C80-polyprenol-phosphate (Larodan Fine Chemicals, Sweden) was added as internal 
standard. After addition of 6 ml methanol and 3 ml 15 M KOH, the sample was 
hydrolyzed for 1 h at 100 °C. Dolichol and Dol-P were extracted with 
chloroform/methanol (2:1 vol/vol) and the chloroform phase was dried under nitrogen. 
The sample was dissolved in methanol/water (98:2 vol/vol) supplemented with 20 mM  
phosphoric acid and applied to a C18 SepPak column (Waters, USA). Dolichol and Dol-P 
were eluted in chloroform/methanol (2:1 vol/vol) followed by separation on a Silica 
SepPak column (Waters, USA). Dol-P was eluted in chloroform/methanol/water 
(10:10:3 vol/vol/vol). Dol-P was fluorescently labeled with 9-anthryldiazomethane 
(Sigma-Aldrich)  in a multi-step procedure described elsewhere (Haeuptle et al., 2010). 
Samples were analyzed by using a LaChrom D-7000 HPLC system (Merck, Germany) 
equipped with an Inertsil ODS-3 column (5 m, 4.6 x 250 mm; GL Sciences Inc., Japan). 
Fluorescence was detected using a LaChrom L-7485 fluorescence detector using 365 nm 
as excitation wavelength and 412 nm as emission wavelength. Separation was done by 
applying isocratic elution with acetonitrile/dichloromethane (3:2 vol/vol) 
supplemented with 0.01% diethylamine (Sigma–Aldrich). Flow was held constant at 1 
ml/min at 30 °C. Statistical analysis was done by paired student t-test. Significance was 
accepted for p < 0.05. 
 
2.8 Radioactive labeling and analysis of dolichol-linked oligosaccharides 
After ethanol exposure, cells were washed with PBS and incubated in serum- and 
glucose-free DMEM (Invitrogen) for 45 min at 37°C. Metabolic labeling of dolichol-linked 
oligosaccharide was performed by addition of 150 μCi [3H]mannose (Hartmann, 
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Germany) for 1 h at 37°C. Cells were washed twice with PBS and scraped in 11 ml 
methanol and 0.1 mM Tris, pH 7.4 (8:3 vol/vol). After the addition of 12 ml chloroform 
and vortexing, cells were pelleted by centrifugation at 5,000 x g for 5 min. Dolichol-
linked oligosaccharides were extracted as described previously and were analyzed by 
HPLC (Burda et al., 1998; Zufferey et al., 1995). Data were subjected to paired t-test for 
statistical analysis. Significance was accepted for p < 0.05. 
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3. Results 
3.1 VA-13 and HepaRG cell lines express ethanol-metabolizing enzymes 
Initially, we assessed the CYP2E1 and ADH activities in the HepaRG and VA-13 cells to 
confirm their validity as ethanol metabolizing cell lines. Expression of murine ADH and 
induction of CYP2E1 were confirmed in VA-13 and HepaRG cells, respectively. ADH 
activity could not be detected in naïve HepG2 cells but was present in VA-13 cells 
(Figure 1 A). CYP2E1 activity could be induced with 2% DMSO treatment for two weeks 
in HepaRG cells (Figure 1 B). The activity of ADH and CYP2E1 was reflected in the 
cytotoxicity towards ethanol (Figure 1 C and D). After 4 d of ethanol treatment, viability 
of VA-13 cells was markedly decreased.  
 
Figure 1. Ethanol-metabolizing enzyme activities and viability in VA-13 and HepaRG cell lines. VA-
13 cells were seeded at 16.7 x 103 cells per cm2 and cultured for 4 days previous to ADH activity 
measurement (A). HepaRG cells were treated as described in Materials and Methods and CYP2E1 activity 
was tested in microsomal proteins of induced and un-induced cells (B). Viable cell count was determined 
after treatment with 100 mM ethanol for 4 days (C and D). 
Publications – Ethanol-induced N-glycosylation deficiency 
   
111 
 
VA-13 sensitivity towards ethanol has been previously described (Clemens et al., 2002). 
Compared to rat liver microsomes, the microsomal fractions of induced HepaRG cells 
showed a 8.6-fold reduced activity of CYP2E1. Induced HepaRG cells showed a similar 
sensitivity to ethanol as the VA-13 cells and viability was reduced by 39% upon ethanol 
treatment. 
 
3.2 Transferrin glycosylation is unaffected by ethanol treatment 
To investigate the production of CDT, hepatocytes were exposed to different 
concentrations of ethanol for 4 days and supernatants were analyzed. Supernatants 
were subjected to isoelectric focusing and immunoblotting against transferrin. 
Transferrin glycoform distribution was different in supernatants of cultured 
hepatocytes compared to blood serum (Figure 2). In contrast to blood serum, 
supernatants showed more prominent asialo- up to trisialo-transferrin bands instead of 
tetrasialo- and disialo-transferrin, which were prominent in healthy control serum. This 
pattern could be observed both cell lines and reflects the aberrant N-glycosylation found 
in hepatic carcinoma conditions (Kamiyama et al., 2013). Moreover, no effect on 
glycoform distribution was visible using concentrations between 25 to 200 mM ethanol. 
With higher ethanol concentrations, less transferrin was detected. The decrease in 
 
Figure 2. Carbohydrate-deficient transferrin as marker for glycosylation deficiency. Transferrin 
was analyzed 4 days after ethanol exposure using isoelectric focusing and subsequent immunoblotting. 
As a comparison, blood serum from a phosphomannomutase 2-CDG patient was analyzed by the same 
procedure. 
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transferrin signal reflected low cell numbers due to ethanol toxicity or may indicate 
impaired protein secretion.  
 
3.3 Transcript analysis reveals potential regulatory changes along the N-
glycosylation pathway 
To get more detailed information of changes occurring in the N-linked glycosylation 
pathway, we analyzed the transcripts of different glycosylation genes that are involved 
in key steps of the Dol-linked oligosaccharide assembly by quantitative PCR after 25 mM 
and 100 mM ethanol treatment for 4 days (Figure 3 A). No significant changes could be 
observed for the analyzed transcripts upon 25 mM ethanol treatment. After treatment 
with 100 mM ethanol, however, the mRNA levels of two genes were slightly changed. 
DPM1, a subunit of DPM synthase, was downregulated by 17%. DPM synthase works as 
a heterotrimer (DPM1-DPM3) transferring a Man-1-P from GDP-mannose to Dol-P. The 
resulting Dol-P-Man serves as a substrate for mannosyl transferases in the ER lumen. 
The second transcript RPN2 was upregulated by 8%. RPN2 is a ribophorin taking part in 
the recruitment of the oligosaccharyl transferase complex to the ER-coupled ribosomes. 
We observed a dose dependency on ethanol concentration as a trend in all the tested 
transcripts. For instance, DPM1 mRNA was decreased at 25 mM ethanol but only at 100 
mM ethanol the change was significant between control and ethanol-treated cells.  
DPM synthase activity was measured to determine whether the lower transcript level of 
DPM1 would affect DPM synthase activity. We found a marked increase in DPM synthase 
activity in cell lysates from ethanol treated VA-13 cells (Figure 3 B). The increase in DPM 
synthase activity stands in contrast with the minor decrease in DPM1 transcript levels. 
Notably, the catalytic subunit of DPM synthase was not affected at the transcriptional 
level. The moderate downregulation in DPM1 transcript together with the 36% increase 
in DPM synthase activity might point to a regulatory mechanism. 
 
3.4 Dolichol-phosphate pool is decreased after ethanol treatment 
Next, we assessed the most prevalent Dol-P species consisting of 90, 95, and 100 carbon 
atoms in hepatoma cells. Treatment of HepaRG cells with ethanol resulted in a decrease 
of Dol-P levels (Figure 4). The strongest decrease was detected for the C95-Dol-P, which 
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was reduced by 80% whereas C100-Dol-P was decreased by 64% in comparison to 
untreated cells (Figure 4 C). 
 
Figure 3. Transcript analysis of the glycosylation pathway in the ER and DPM synthase activity 
after 100 mM ethanol treatment. Transcript analysis was performed from RNA of VA-13 cells treated 
with 25 or 100 mM ethanol for 4 days (A). Results are shown as mean ± SEM of four independent 
samples. *, p < 0.05. Enzyme activity was determined using cell lysates from treated or untreated VA-13 
cells in an assay using C95-Dol-P as acceptor and radioactive GDP-[3H]mannose as donor substrate (B). 
The radioactivity of labeled C95-Dol-P-Man was quantified by liquid scintillation counting. Activities 
shown as mean ± SEM of six independent experiments. *, p < 0.05. 
 
3.5 N-glycan precursor assembly is impaired after ethanol treatment 
In CDG types that affect the biosynthesis of the N-glycan precursor, different 
intermediate dolichol-linked oligosaccharides can accumulate. To address ethanol- 
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Figure 4. Dolichol-phosphate levels after 100 mM ethanol treatment. Dol-P levels were determined 
in HepaRG cells after 4 d of ethanol treatment. C90, C95, and C100 peaks were identified using Dol-P 
standards and quantitative determination was done with using C80-Dol-P as internal standard. 
Representative HPLC profiles are shown (A, B). Peak areas were determined and analyzed (C). Data 
represent mean values ±SEM of three independent experiments. *, p < 0.05. 
 
induced changes in N-glycan precursor assembly, we metabolically labeled dolichol-
linked oligosaccharides with [3H]mannose and subsequently separated them by HPLC 
coupled to a flow scintillation analyzer. The dolichol-linked oligosaccharide profile 
underwent a shift, displaying a smaller fraction of the final oligosaccharide precursor 
when cells were treated with 100 mM ethanol (Figure 5 A , B). A reduction of the 
GlcNAc2-Man9-Glc3 peak by 27% was observed in HepaRG cells indicating either a lower 
availability of dolichol leading to a general decrease is dolichol-linked oligosaccharide or 
a defect in a later stage of the N-glycan biosynthesis in the ER. Typically, defects more 
Publications – Ethanol-induced N-glycosylation deficiency 
   
115 
 
early in the biosynthesis lead to an accumulation or a uniform decrease of dolichol-
linked oligosaccharide precursors (Figure 5 C). The same trend of a reduced GlcNAc2-
Man9-Glc3 peak could be observed in VA-13 cells (Figure 5 D). 
 
 
Figure 5. Dolichol-linked oligosaccharide analysis. VA-13 and HepaRG cells were metabolically 
labeled with [3H]mannose to analyze dolichol-linked oligosaccharide precursors. Representative control 
and 100 mM ethanol treated sample profiles are shown (A and B). Relative peak areas of the 
GlcNAc2Man9Glc3 to total area were calculated (C and D). Data represent mean values ±SEM of three 
independent experiments. *, p < 0.05. 
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4. Discussion 
We investigated the effect of ethanol exposure on N-linked protein glycosylation and 
observed lower Dol-P levels, in particular C95-Dol-P in our HepaRG model. Lower 
dolichol levels have been reported previously in murine model systems upon ethanol 
treatment (Cottalasso et al., 1998; Cottalasso et al., 1996). Dol-P is critical for N-
glycosylation in two ways. First, it serves as a carrier for the N-glycan precursor. Second, 
Dol-P coupled to Man or Glc is essential for glycosyltransferases located in the ER lumen. 
Accordingly, low availability of Dol-P-Man in DPM1-CDG was previously demonstrated 
to be attenuated by increasing Dol-P thereby compensating the low activity of DPM 
synthase with better substrate availability (Haeuptle et al., 2011). The strategy of 
increasing dolichol levels to attenuate glycosylation deficiency in ALD would be 
interesting but might not be sufficient due to the complexity of ethanol-induced N-
glycosylation deficiency.  
This is the first study showing ethanol-induced effects on the biosynthesis of the N-
glycan precursors, namely a reduction of Dol-PP-GlcNAc2Man9Glc3 compared to 
untreated cells. Interestingly, while general decrease in dolichol-linked oligosaccharide 
is well defined in CDG, such a reduction of the final dolichol-linked precursor has not 
been observed yet, neither in inherited nor in acquired glycosylation deficiencies. The 
dolichol-linked oligosaccharide pattern suggests a deficiency in the ER luminal assembly 
of the N-glycan precursor or could be a consequence of lower dolichol levels. CDG 
research has shown that deficient enzymes of the early, cytosolic steps of N-glycan 
precursor biosynthesis preferentially lead to an accumulation of Dol-P precursors, such 
as Dol-PP-GlcNAc2-Man5 in DPM1-CDG (Imbach et al., 2000). The shortage in dolichol 
could also explain the lower Dol-PP-GlcNAc2Man9Glc3 levels with decreased availability 
of the N-glycan precursors, leading to drainage of the dolichol-linked oligosaccharide 
pool. CDG with deficient dolichol or Dol-P biosynthesis typically result in reduced 
dolichol-linked oligosaccharide but do not alter the distribution of the dolichol-linked 
precursors as observed in DOLK-CDG (Kranz et al., 2007). In SRD5A3-CDG, the 
polyprenol reductase along the dolichol biosynthetic pathway is non-functional but does 
not lead to decreased dolichol levels and fibroblasts show a healthy dolichol-linked 
oligosaccharide distribution (Grundahl et al., 2012). Symptoms on the systemic level are 
not shared by CDG affecting dolichol biosynthesis and ALD.  The tendency of CDG for 
liver malformation or disease is apparent in other forms of CDG with defects in later 
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steps of the N-linked glycosylation pointing towards a more complex mechanism in N-
glycosylation deficiency in ALD. 
Transcriptional regulation of N-glycosylation genes could explain ethanol-induced N-
glycosylation deficiency. We found a trend for transcript alteration upon ethanol 
treatment but only to a marginal extent. DPM1, a subunit of the DPM synthase, was 
transcriptionally downregulated by 17% indicating a regulatory mechanism. This notion 
is supported by our observation that DPM synthase activity was increased by 36%. More 
work is needed to elucidate possible regulatory mechanisms for the N-glycosylation 
pathway in ALD. Since reduced Dol-PP-GlcNAc2Man9Glc3 might be due to dysfunction of 
the later, luminal steps of the N-glycan precursor assembly, a deregulation of the 
oligosaccharyl transferase (OST) offers an explanation. Indeed, we found an indication 
for potential OST deregulation. RPN2, a part of the OST complex, was slightly 
upregulated. RPN2 was shown to promote glycosylation of P-glycoprotein, an ABC 
transporter of the multidrug resistance family (Honma et al., 2008; Kerb et al., 2001). 
Knock-down of RPN2 resulted in reduced glycosylation as well as reduced membrane 
localization of P-glycoprotein. We speculate that RPN2 upregulation upon ethanol-
treatment induces changes in N-linked glycosylation of RPN2 target proteins 
contributing to an aberrant dolichol-linked oligosaccharide pattern. It would be 
interesting to further investigate the expression and function of OST subunits in order to 
get a notion of the impact of ethanol on OST activity. 
 
5. Conclusion 
In conclusion, we found that decreased Dol-P and altered dolichol-linked 
oligosaccharide profiles contribute to ethanol-induced N-linked glycosylation deficiency. 
Furthermore, altered transcription of genes along the N-linked glycosylation pathway 
was found indicating a deregulation in N-glycosylation. Together with previous findings 
of lower sialyltransferase and higher sialidase activities, ethanol-induced glycosylation 
deficiency proves to be a result of metabolic interferences along the N-glycosylation 
biosynthetic pathway starting from the early steps of dolichol synthesis, continuing with 
the biosynthesis of the N-linked glycan precursor, and concluding with the final steps of 
glycan capping in the Golgi apparatus. 
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GENERAL DISCUSSION 
Considering the immense abundance of glycans on cell surfaces and secreted proteins, 
countless essential biological functions depend on glycosylation. However, glycobiology 
has been a comparatively small field of research so far. Although glycobiologists are very 
active in promoting their field, glycobiology has received relatively little attention in 
other areas of biological sciences. In part, this was due to the gap of knowledge about the 
significance of glycosylation but also due to restricted possibilities regarding efficient 
methods to analyze the almost unmanageable complexity of sugar structures. With the 
advent of advanced technologies such as high-throughput mass spectrometry in 
conjunction with powerful computational software, glycans have moved within reach of 
researchers other than glycobiologists (Kolarich et al., 2013; Mechref et al., 2012; Zaia, 
2010; Zaia, 2013). Additionally, progress in glycobiology prompted other scientists to 
consider glycobiological aspects in their field of research. Consequently, the significance 
of glycosylation is being discovered in many fields including cancer research, 
immunology, virology, and developmental biology. This development is highly beneficial 
for the understanding of glycans and their functions. 
Initially, glycans were merely considered decorating structures on cell surfaces of all 
kind of cell types in all the domains of life. The significance of these “decorations” for 
humans was first realized with the discovery of the ABO blood groups in 1900 
(Landsteiner, 1900). At the time, the nature of the determinants was totally elusive but 
the consequences for blood transfusion were immense. Nearly 60 years later, Morgan 
and Watkins defined sugars to be the blood group determinants (Morgan and Watkins, 
1959; Watkins and Morgan, 1959). Later, the first carbohydrate-deficient glycoprotein 
syndrome was discovered (Jaeken et al., 1980). The patients suffered from mental 
retardation, muscular hypotonia, failure to thrive, inverted nipples, and abnormal fat 
deposits. Carbohydrate-deficient transferrin (CDT) was defined as a marker for CDG 
using isoelectric focusing of blood serum. Only fifteen years after its discovery, a 
phosphomannomutase deficiency was defined as the molecular basis of this CDG (Van 
Schaftingen and Jaeken, 1995). In the meantime, a CDG with a different CDT profile was 
discovered with a defect in GnT-II. It was termed CDG-II (Jaeken et al., 1994; Ramaekers 
et al., 1991). The discovery rate of novel forms of CDG was rapidly increasing and greatly 
contributed to the understanding of the glycosylation pathways. Yeast models have been 
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instrumental by comparison of DLO profiles of yeast mutants with DLO profiles of CDG 
patients thereby identifying genes of the glycosylation machinery in yeast and 
subsequently confirmation of the mutation in CDG patients by gene sequencing (Aebi 
and Hennet, 2001). Considering the 2% fraction of the genome that is involved in 
glycosylation, it can be speculated that the majority of CDG types is yet to be discovered. 
Recently discovered forms of CDG surprisingly do not have the typical symptomatic 
picture but show tissue- or organ-specific impact. In DHDDS-CDG, for instance, retinal 
degeneration is the single apparent symptom (Zelinger et al., 2011). DHDDS is the 
dehydrodolichyl diphosphate synthase which catalyzes the synthesis of polyprenol-PP 
from two molecules of farnesyl-PP. Thus, DHDDS is crucial for Dol biosynthesis and the 
implications of a defective DHDDS would seem to cause a much broader spectrum of 
symptoms. Either the discovered DHDDS-CDG cases have enough residual polyprenol-PP 
production from mutated DHDDS or another enzyme can compensate for the loss in 
DHDDS activity. Retinis pigmentosa is a manifestation well known in CDG as it occurs 
also in mevalonate kinase deficiency and PMM2-CDG (Goldfinger, 2009; Grunewald, 
2009). 
 
The challenge of uncovering regulatory mechanisms  
The pathways of glycosylation in humans are well defined and all the N-linked 
glycosylation steps are assigned to enzymes (Haeuptle and Hennet, 2009; Jaeken, 
2010b). However, parallel pathways to the ones already discovered are more difficult to 
identify partly because of the more complex human genome compared to model systems 
like yeast. Some of the pathways are specific to vertebrates or even restricted to 
mammals (Dell et al., 2010). Moreover, deficient enzymes involved in more peripheral 
functions such as regulatory enzymes or tissue specific glycosylation-associated genes 
render a characterization more difficult because of the difficulty to detect such defects 
unlike the strong phenotype of classical CDG. Generally, the regulation of the 
glycosylation machinery is elusive. Importantly, pathways with global contributions to 
an organism are highly regulated as can be seen in metabolic pathways but also signal 
transduction or gene regulation (Alberts, 2008). Regulation of glycosylation seems likely 
to be tightly regulated especially during development of the embryo since CDG patients 
have severe, multisystemic defects in early childhood (Haltiwanger and Lowe, 2004; 
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Jaeken, 2010a). Additionally, mechanisms of development of CDG have not been defined 
yet. Investigations in this direction are difficult, though. An promising approach is a 
switch system in which genes can be turned on and off at certain points in development 
using mouse models. 
We encountered a possible regulatory mechanism for N-linked glycosylation in liver 
cells exposed to ethanol. ALD is unique due a non-systemic ethanol-induced N-
glycosylation deficiency of liver proteins. We tested the effect of ethanol on N-linked 
glycosylation in a cell culture model using two hepatic carcinoma cell models to define 
N-linked glycosylation deficiency in ALD. Ethanol exposure led to decreased Dol-P levels 
supporting previous experiments with ethanol-fed rats and particularly the C95 species 
was dramatically decreased (Cottalasso et al., 1998; Cottalasso et al., 1996). As a 
possible consequence, we found a decreased amount of the N-glycan precursor. This was 
the first characterization of Dol-linked oligossacharide profiles in ethanol-induced N-
glycosylation deficiency. To investigate gene regulation at the transcriptional level, we 
tested the glycosylation genes taking part in ER glycosylation steps. Interestingly, we 
found a dose dependency of transcription on ethanol concentration as a trend. 
Transcription of two genes was significantly changed. DPM1, a component of the 
trimeric DPM synthase, was downregulated whereas RPN2, a regulatory subunit of the 
OST, was upregulated. To obtain a hint whether the transcriptional changes might be of 
regulatory nature, we tested the activity of DPM synthase and found a strong 
upregulation of enzymatic activity. How this potential regulatory mechanism is 
governed has yet to be investigated for instance by determination of the dose-
dependency of DPM synthase activity and DPM1 transcriptional downregulation on 
ethanol concentration and by looking at the correlation of activity and transcript level. 
In case of RPN2, we can only speculate about the effect of this upregulation due to the 
complexity of the OST which can consist of different subunits possibly targeting 
different sets of proteins or even individual proteins (Vleugels et al., 2009). 
Identification of RPN2-specific N-glycosylation targets could provide a readout for our 
findings. 
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Therapeutics for glycosylation disorders 
While novel forms of CDG are being discovered, efforts to treat the known forms of CDG 
have been undertaken. However, treatment for CDG is principally limited to post-natal 
patients because of the lack of pre-natal tests for CDG (Funke et al., 2013). Glycosylation 
is crucial for development and proper functioning of a variety of organ systems, 
particularly for the nervous system evident from the neurological component of most 
CDG. Unfortunately, neurological deficits in CDG are not treatable with present-day 
medicine. In order to find therapeutic targets, identifying mutations in the genome is not 
enough. High-throughput sequencing methods like whole-exome sequencing enable 
screening of patients with inherited diseases to pinpoint mutations (Freeze, 2013). 
However, biochemical read-outs are required to confirm candidate genes and potential 
treatments need to be validated for improvements of biochemical parameters. 
MPI-CDG is a special case of CDG due to the usual lack of neurological symptoms 
(Westphal et al., 2001). This lack indicates that the defect does not manifest already 
during development but is important for maintaining the function of developed organs. 
However, the liver and gastrointestinal tract are affected. Symptoms include vomiting, 
diarrhea, gastrointestinal bleeding, protein-losing enteropathy, hepatomegaly, and liver 
fibrosis during childhood and they improve in adulthood. Severe cases show 
coagulopathy, hypoglycemia, and thrombosis. Nutritional mannose supplementation has 
been successful in relieving many of the symptoms (Babovic-Vuksanovic et al., 1999; de 
Lonlay et al., 1999; Niehues et al., 1998; Penel-Capelle et al., 2003; Westphal et al., 2001). 
Besides MPI-CDG, only two other CDG were reported to respond to treatment (Jaeken, 
2010a). In SLC35C1-CDG, the deficiency in the GDP-Fuc transporter in the Golgi network 
can be compensated with fucose supplementation in some cases (Hellbusch et al., 2007). 
In PIGM-CDG, histone histone acetylation at the PIGM promotor is impaired and thus 
lowers PIGM-dependent mannosyltransferase transcription (Almeida et al., 2006). Using 
butyrate to inhibit histone deacetylase increased PIGM transcription and stopped 
seizures. Considering yet undiscovered CDG with non-developmental symptoms, 
medical treatment could help to attenuate manifestations caused by impaired 
glycosylation. Delivery of the medication is critical of course and in case of mannose 
supplementation an easy task. Recently, prenatal mannose treatment of mice with an 
engineered PMM2 defect has proven successful. Embryonic lethality of the hypomorphic 
PMM2 mutation could be overcome by mannose administration to the mother 
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(Schneider et al., 2011). The mannose-treated PMM2-defective embryos showed no 
manifestations of CDG. These examples demonstrate the main difficulties when it comes 
to CDG treatment. First, CDG affecting development, which include most CDG, require 
pre-natal treatment and need to be identified by methods that are not yet available. 
Second, pre-natal treatment is more difficult because treatment usually is applied on the 
mother and is restricted by the placenta barrier (Giaginis et al., 2012; Vahakangas and 
Myllynen, 2009). In case of non-developmental effects, the efficiency of medication 
greatly depends on sufficient residual activity of the affected enzyme. Importantly, 
development of medication for rare diseases is financially unattractive and therefore 
mannose treatment for MPI-CDG treatment has been a lucky exception due to its low 
cost and easy application. 
In this work, we tested a therapeutic approach to treat DPM1-CDG. We exploited the 
action of Zaragozic acid, a cholesterol-lowering drug that differs from the classical 
statins. Zaragozic acid was discovered in a screen for cholesterol-lowering compounds 
in the context of cardiovascular disease treatment (Bergstrom et al., 1995). It inhibits 
squalene synthase which is active at a bifurcation in the mevalonate pathway. The 
bifurcation divides into cholesterol biosynthesis – through the action of squalene 
synthase – and into Dol biosynthesis (Welti, 2013). We could show that supplying 
fibroblasts with the squalene synthase inhibitor Zaragozic acid improved N-linked 
protein glycosylation and GPI-anchor formation in DPM1-CDG (Haeuptle et al., 2011). As 
expected, inhibition of squalene synthase resulted in lower cholesterol and higher Dol-P 
levels. We speculated that higher Dol-P levels could compensate for the insufficient DPM 
synthase activity. Indeed, Dol-P-Man levels could be restored. Moreover, Dol-linked 
oligosaccharide and N-linked oligosaccharide profiles were partly normalized and were 
reminiscent of healthy oligosaccharide profiles. Moreover, GPI anchor availability was 
improved as assessed by the expression of the GPI-anchored membrane surface protein 
CD59. With this work, we provided a first step in DPM1-CDG therapy. We used an 
available drug that was shown to be well tolerated at least in rats and confirmed the 
treatment success by measuring biochemical readouts (Baxter et al., 1992; Bergstrom et 
al., 1993). Whether such a treatment could attenuate DPM1-CDG manifestations at the 
level of an entire organism, needs further confirmation for instance using an animal 
model. 
 
Discussion 
    
127 
 
Future directions 
Considering the 2% of genes that are predicted to be involved in glycosylation 
processes, it is safe to speculate that glycobiology plays an important – even if not yet 
fully recognized and defined – part in other diseases like cancer, immune disorders, or 
infectious diseases (Freeze et al., 2012). We showed, for instance, that glycosylation is 
perturbed at the level of Dol-linked oligosaccharide assembly in ethanol-treated 
hepatoma cells. This is likely to be associated with lower Dol levels. The specific 
consequences of underglycosylation of blood proteins as found in ALD are difficult to 
estimate due to the impact of chronic alcohol consumption on multiple organ systems 
(Wang et al., 2010). Future studies might assess the contribution of glycosylation 
deficiency to the clinical picture of ALD and other consequences of alcoholism. 
Importantly, connecting glycobiology to other fields of research is beneficial in many 
ways. Awareness of glycan functions can be raised, more knowledge about mechanisms 
in regulation of glycosylation can be gained, and possibly novel therapeutic targets in 
CDG could be identified. In this way, glycobiologists can profit from the attention and 
knowledge of other fields as we demonstrated by using cholesterol-lowering Zaragozic 
acid found in the fight against cardiovascular disease to improve glycosylation in DPM1-
CDG. In ALD, liver fibrosis is a well-known characteristic as it is in certain forms of CDG 
(Jaeken et al., 1998; Pelletier et al., 1986). Efforts to uncover mechanisms how liver 
fibrosis develops in CDG might help to understand liver fibrosis in ALD given the 
common deficiency in N-glycosylation. Vice versa, understanding the development of 
ethanol-induced glycosylation deficiency might reveal regulatory mechanisms for N-
linked glycosylation. 
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